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 BACKGROUND- Children with Autism Spectrum Disorder (ASD) demonstrate 
a physiological imbalance between free radicals, resulting from oxidative stress, and 
antioxidants. Oxidative stress is linked to the pathogenesis of this neurocognitive 
disorder. The objectives of this pilot feasibility study: 1) to examine the effect of 
consumption of high concentration antioxidant cacao on behavior of children as 
perceived by the child’s teacher and 2) as perceived by the child’s parent. 
 METHODS- This clinical trial was a prospective experimental study. Participants 
consumed 8 squares (or 16 grams) per day of the dark chocolate which had a 
concentration of 70% cacao and 30% organic cane sugar (total antioxidant concentration 
was 8,320 µmoles / 100 grams. The two main behavioral measures were the Aberrant 
Behavior Checklist- 2nd Edition (ABC-2) and the Autism Spectrum Rating Scale (ASRS) 
which were completed by the child’s teacher at baseline and end of week four; and by the 
child’s parent at baseline, week two, and week four.  
 RESULTS- Twelve teachers and children with ASD (9 males, 3 females, mean 
age of 10.9 ±3.9 years) participated in this study. Teachers noted significant 
improvements on the Autism Spectrum Rating Scales of Social/Communication (p=0.03, 
 xii 
η2=0.79), Unusual Behaviors (p=0.02, η2=0.70), and Self-Regulation (p=0.04, η2=0.59). 
No significant changes were noted on any of the Aberrant Behavior Checklist-2 subscales 
(p>.05). For the second study, sixteen parents and children with ASD participated in the 
study (12 males, 4 females, aged 4 to 17 years). Parent reports showed significant 
improvements on the ABC-2 subscales of Irritability (p= .03, η2 = 0.25), Social 
Withdrawal (p=.01, η2 = 0.29), Stereotypic Behavior (p=.05, η2 = 0.13), 
Hyperactivity/Noncompliance (p=.04, η2 = 0.20), and Inappropriate Speech (p=.05, η2 = 
0.16). Significant improvements were noted on the ASRS scales of 
Social/Communication (p=.04, η2 = 0.25), Unusual Behaviors (p=.003, η2 = 0.20), Self-
Regulation (p=0.02, η2=0.32), and Total Scores (p<.001, η2=0.54). 
 CONCLUSION- Results from this study support the therapeutic benefit of 
antioxidants in improving social communication, unusual behaviors, and self-regulation 
behaviors of children with ASD. Further robust randomized controlled trials are 
necessary to elaborate the validity of these finding. 
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CHAPTER 1 
INTRODUCTION AND REVIEW OF THE LITERATURE 
Autism Spectrum Disorder 
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder that is 
characterized by deficits in social and communication skills, functional impairments 
across multiple settings, repetitive and restrictive behaviors, as well as hyper or hypo 
responsiveness to sensory stimuli in the environment 1. According to the Center for 
Disease Control and Prevention (CDC), currently in the United States (U.S.), 1 in 68 
children are identified as having ASD with it being four and a half times more prevalent 
in males than females 2. According to the World Health Organization (2017), worldwide, 
one in 160 children have ASD. Although the etiology of ASD remains elusive, there are 
genetic, environmental, immunological, and oxidative stress influences that are related to 
the pathogenesis of the disorder 3,4. 
Additionally, perinatal and neonatal risk factors such as, “abnormal fetal 
presentation, umbilical-cord complications, fetal distress, birth injury or trauma, multiple 
birth, maternal hemorrhage, summer birth, low birth weight, small for gestational age,” 
among others have been identified as part of the association with ASD 5. The 
heterogeneity of ASD lends itself to the need for a variety of interventions, both 
traditional and non-traditional, as no one technique works across the spectrum. 
  
Traditional Therapies 
Behavioral therapists, speech and language pathologists, and occupational 
therapists are common interventionists that work with children on the spectrum. 
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Behavioral therapists work with ASD children on maladaptive behaviors, language skills, 
daily living skills, and social functioning. This type of applied behavioral analysis 
(ABA), uses a Skinner approach with rote discrete trials in a one on one setting and is 
typically recommended at 40 hours per week for years on end 6,7. Speech and Language 
Pathologists also work with children with ASD to target social communication skills, 
request making, speech production, alternative communication strategies, and reciprocal 
interaction skills (American Speech-Language-Hearing Association, 2006). Occupational 
therapists target sensory processing skills through regulatory strategies across 
environments, activities of daily living related to school and home performance, and 
motor skills required for activities in their educational setting 9. In general, behavioral 
therapists work on maladaptive behaviors, speech therapists work on communication 
skills, and occupational therapists work on self-regulation skills as they relate to hypo or 
hyper responses to environmental stimuli. 
 
Behavioral Therapy 
Early intensive behavioral intervention (EIBI) is a common behavioral approach 
used in children with ASD. It is typically recommended for 40 hours per week for a 
minimum of two years 6. A meta-analysis on the effectiveness of this approach revealed 
that children in experimental groups had better IQs and adaptive behavior outcomes 
compared to control groups who received a less intense approach 6. Although ABA 
techniques are common and popular in addressing aberrant ASD behaviors, the evidence 
remains mixed as studies did not have a uniform or equally replicable methodology to 
show consistency of results. 
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Special Education and Autism 
Children with ASD often receive the aforementioned services through their 
special education program. Furthermore, it should be noted that both special education 
and general education teachers educate students with ASD 10. Evidence based practices 
are limited in nature for the ASD population due to the heterogeneous profiles of the 
disorder and often times practitioners implement a variety of strategies that have not been 
studied in combination 11. Additional barriers for educators and practitioners include the 
child’s behaviors which make conducting standardized assessments challenging to 
accurately develop goals and treatment plans in the school environment 12. Overall, there 
is limited evidence on teachers’ perceptions of ASD behaviors in the classroom setting 
yet these behaviors bring challenges when it comes to educational engagement from the 
ASD student. 
 
Family Stress and Autism 
As with any disease or disorder that has a life-long course, the stress of being a 
parent or caregiver of a child with ASD naturally comes with the territory.  The child’s 
behaviors, including but not limited to, anxiety, tantrums, self-injury, or outbursts may 
cause the family unit additional stress making daily life tasks more burdensome 13.  
Parents have reported feelings of anger, doubt, and disbelief at the time of their childs’ 
diagnosis 13. Additionally, maladaptive behaviors had a negative effect on parent sleep 
and many parents reported missing work or quitting work as a result 13. Parental stress 
should also be considered when weighing the consequence of aberrant behaviors of 
children with ASD. These ripple effects on the family unit show the colossal impact that 
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ASD behaviors can have and as a result require our attention to address and alleviate as 
much as possible.  
 
Pharmacological Interventions 
In terms of pharmacological interventions, approximately one third of the ASD 
population take Selective Serotonin Reuptake Inhibitor (SSRIs) drugs because their 
behaviors are similar to other serotonin related disorders 14. There are only two Food & 
Drug Administration (FDA) approved drugs for ASD, Risperidone and Abilify 14. 
Risperidone is a second-generation antipsychotic that has helped children with ASD 
reduce their number of tantrums, aggressive behaviors, and self-injurious behaviors 14. 
Abilify is a psychotropic drug designed to treat mood irritability in children with ASD 
14,15. However, as with any drug, there are associated adverse effects including increased 
appetite, weight gain, dizziness, drooling, drowsiness, fatigue, vomiting, nasopharyngitis, 
fever, insomnia, and upper respiratory infections 14-16. Non-pharmacological lifestyle 
oriented interventions may compliment traditional therapies in targeting behavior, mood, 
and performance issues associated with ASD without side effects of medication 17.  
When the aforementioned therapies and pharmaceutical agents are considered the 
cost of ASD becomes colossal. A recent study reported that the cost of ASD, across one’s 
lifetime, in the U.S. is $1.4 million, and $2.4 million, respectively, if they also have an 
intellectual disability 18. However, as with any disability or disorder the cost is indefinite 
as there are also psychological and stress costs that cannot be quantified for the 
individuals or families caring for them. Lifestyle oriented approaches may, then, be 
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necessary not only to potentially offset costs but to improve quality of life in a long term 
sustainable fashion. 
 
A Physiological Perspective: Oxidative Stress 
Oxidative stress leads to an excess accumulation of free radicals in the body and 
has been linked to a variety of diseases including cancer, cardiovascular disease, 
neurological diseases, pulmonary disease, rheumatoid arthritis, nephropathy, epilepsy, 
allergies, inflammation, as well as ocular disease 19,20. Although oxygen is a life 
sustaining necessity, the influence of oxidative stress causes oxygen to have harmful 
effects on the human body 21. Oxidative stress can be simply defined as disequilibrium 
between reactive oxygen species (ROS), also known as free radicals, and antioxidants 
(Hossain, ASM Matiur, & Alam, 2014). Essentially these ROS donate oxygen to 
otherwise stable molecules and thus disrupt their function by oxidizing them 21. This 
imbalance can damage any one of our organ systems and can alter DNA structure and 
compromise the integrity of cellular membranes (Hossain, ASM Matiur, & Alam, 2014). 
Furthermore, the human brain occupies approximately two percent of our body weight 
yet utilizes a quarter of our energy required at rest 23. This is important in the pediatric 
population because young children are highly susceptible to oxidative stress during early 
development because their protective barriers against oxidative damage are not fully 
formed. 
Though the exact mechanisms on the pathogenesis of neurocognitive disorders 
remains under scientific investigation, there is an identifiable link between the excess of 
free radicals and neuronal damage. Recently, scientists have also studied oxidative stress 
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as part of the pathophysiology of ASD, as well its potential link to other neuropsychiatric 
disorders such as schizophrenia, major depressive disorder, anxiety, panic disorder, 
Alzheimer’s disease, Parkinson’s disease, and obsessive compulsive disorders 3,23. Due to 
the brain’s high energy requirements, specifically neurons, which require the most energy 
of any brain cell are limited in their antioxidant defense making them the first cells to be 
negatively impacted 23. It is clear that the deleterious effects of oxidative stress can 
significantly impact brain and cellular function of many organ systems. 
 
Oxidative Stress and ASD 
 Although the etiology of ASD is multifactorial, research suggests that there are 
some neurophysiological differences between individuals with and without ASD 24,25. For 
example, irregularities in neuronal connections have been associated with “cognitive, 
social, and sensory behavioral symptoms,” (Dinstein et al., 2011, p. 1218). Furthermore, 
due to the limited number of studies that have examined where the brain abnormalities 
are and the various regions studied it is difficult to determine if the differences are 
localized in the brain or more systemic 25. Of particular relevance to the current study is 
research on oxidative stress and ASD symptomology. Damodaran, Arumugam 3 reported 
a significant increase in oxidative stress markers in children with ASD compared to 
matched controls and the level of antioxidants excreted in urine samples were 
significantly lower in children with ASD compared to matched controls. Furthermore, the 
severity of autistic behaviors was positively correlated with oxidative stress markers, 
whereas antioxidant levels were negatively correlated with autistic behaviors 3,26.   
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Additional evidence from Ming et al. (2005), who measured urinary excretion of 
8-iisoprostane and 8-hydroxy-2-deoxyguanosine in children with ASD and matched 
controls and found that children with ASD had increased levels of lipid peroxidation, 
indicating further mechanism for oxidative stress patterns. In addition, elevated blood 
samples of glutathione, glutathione peroxidase, methionine, oxidized glutathione, and 
cysteine have also been found in children with ASD 26.  Since free radicals, when in 
excess, can be so deleterious to mind-body health it is imperative that antioxidants be 
incorporated as supportive therapies for neutralizing oxidative stress. 
Ming and colleagues (2005) suggests that children with ASD tend to have greater 
markers of oxidative stress compared to age matched controls or their non-Autistic 
siblings. Oxidative stress can be due to mitochondrial impairment, environmental factors, 
metabolic issues, and genetic predisposition 20,25. In turn, oxidative stress can lead to a 
cascade of events such as inflammation, damage to cell membranes, autoimmunity, 
methylation damage, cell death, and neurological impairments 26. Oxidative stress can be 
identified through markers of antioxidant enzymes, lipid peroxidation, and protein 
oxidation, all of which are higher in children with autism compared to their matched 
controls 3,20,25. It is evident that this imbalance between free radicals and antioxidants 
creates a plethora of detrimental physiological outcomes and are contributory to the 
pathogenesis of ASD. In summary, these studies provide growing evidence regarding the 
physiological differences in children with ASD that show an imbalance in the oxidation 
of antioxidants and thus an excess of free radicals. 
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Antioxidants and Nutrition 
The human body offers natural mechanisms to counter the damaging effects of 
free radicals that lead to oxidative stress by producing antioxidants. Antioxidants can be 
produced endogenously by the body or can be ingested through dietary nutrients. 
Endogenous antioxidants include glutathione, ceruloplasmin, transferrin, catalase, 
superoxide dismutase, and glutathione peroxidase 4. Examples of dietary antioxidants 
include but are not limited to Vitamin E, Vitamin C, Beta-carotene, Lycopene, Selenium, 
Omega-3 fatty acids, Omega-6 fatty acids, and Flavonoids 19. Polyphenols are also 
considered a larger category of antioxidants which are phytochemicals that are found in 
large quantities in fruits, vegetables, and other natural nutrients 27.  
Many antioxidant rich foods and vitamins have been used in the treatment of 
disease 28. For example, vitamin C and vitamin E are both rich in antioxidants and have 
been used for cardiovascular disease and cancer 28. Carotenoids have also been used in 
diseases that are neurodegenerative, inflammatory, or cardiovascular in nature 28. 
Additionally, polyphenols such as flavanols and flavonoids have free radical scavenger 
properties making them beneficial in combatting chronic diseases 29. The cocoa bean has 
higher antioxidant properties than teas and wines as they have higher concentrations of 
flavonoids making it a highly valuable nutrient in health promotion 29. Overall, 
antioxidants can be considered beneficial for protection against chronic diseases and are 
often found in functional super foods such as berries, cacao, and green tea 30. 
To date, there is not an antioxidant specific validated and reliable nutrition survey 
that applies to children or adults. However, the Youth Adolescent Food Frequency 
Questionnaire is a validated measure developed out of Harvard 31. The questionnaire 
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comprises nine main content areas of foods frequently consumed; eight questions on 
demographics, 20 questions on consumption of various beverages, 16 dairy food items, 
30 questions on main dishes, six questions on types of sandwiches, eight questions on 
other food consumption, 17 questions on breads and grains, 41 questions on fruits and 
vegetable consumption, and 31 questions on snacks and desserts. The questions are 
ranked depending on how frequent the food items are consumed; from never to less than 
once per month, one to three times a week, once per week, two to four times per week, 
more than four times per week, and once per day. The category related to fruits and 
vegetables is the closest measure of children’s intake of foods that would be rich with 
antioxidants and thus this questionnaire was employed in this study. 
  
Cacao as an Antioxidant 
In the typical U.S. diet, chocolate is the leading source of antioxidants followed 
by fruits and vegetables 32. Cocoa is potent in antioxidants such as flavanols which play a 
role in neuroregulatory mechanisms such as anti-inflammation and vasodilatory 
properties 33. Polyphenols, such as those found in cacao, are known to have the ability to 
remove free radicals from the body and can offer protective properties in disease such as 
arteriosclerosis, heart disease, and alcoholic fatty liver 28. In addition, flavanoids have 
potent antioxidant content and are derived from foods such as cacao, green tea, grapes, 
apples, ginkgo biloba, berries, among other foods 19. Antioxidants found in cacao include 
several subclasses such as polyphenols, flavonoids, and flavanols. Within flavanols, we 
find catechin, epicatechin, epigallocatechin, and epigallocatechin gallate all of which are 
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found naturally in cacao 29,34. Consequently, it is evident that dietary antioxidants can be 
easily consumed and beneficial for overall health.  
Thus, although oxidative stress is associated with a variety of neurological 
disorders, promising research from ASD and Down Syndrome participants suggests that 
the counteracting effects of antioxidants may minimize free radical damage, thereby 
reducing symptoms of irritability, hyperactivity and improving the physiological balance 
between free radicals and antioxidants 35,36. For example, in a recent study on children 
and adolescents with Down Syndrome, researchers found support for antioxidant 
supplementation through use of vitamin E, vitamin C, E-TABS, and Energil C in 
reducing oxidative stress biomarkers with lasting effects even after the six-month 
intervention 36. Nutrition plays an integral role on health via antioxidants. Antioxidants 
have great physiological and neurological benefit given their defense against toxic free 
radicals when normal mechanisms experience disequilibrium.  
Oxidative stress biomarkers are particularly noteworthy as they have the potential 
to be modulated by means of non-pharmacological interventions, such as nutritional 
interventions. Cacao is a food rich in flavonoids and their sub group flavanols. For the 
purposes of this introduction, cacao and cocoa were used interchangeably. Both are 
associated with improved cognitive processing, alertness, and processing speed 37. 
Further benefits of cocoa include increased cerebral blood flow, improved cardiovascular 
activity, improved insulin resistance, improved blood pressure, and improved endothelial 
function 37. Antioxidants’ benefits include improvement of cellular structure, neutralizing 
free radicals, neuroprotective, anti-inflammatory, accumulation in the hippocampus and 
cortex, and improvement of vascular endothelial function 27,32,34.  
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More specifically, cacao is a natural and potent antioxidant with benefits linked to 
improvements in blood pressure, lipid peroxidation, cognitive response time, gamma 
frequency, and cerebral blood flow 27,32,38-40. Additionally, flavanoids’ ability to cross the 
blood brain barrier demonstrates their neuroprotective mechanisms as well as their role in 
cognitive functions such as learning and memory 34,41. The aforementioned studies 
summarize the inherent value in cacao as a natural superfood the mind and the body.  
Scholey, French, Morris, Kennedy, Milne, Haskell 42 studied healthy adults and 
randomly assigned participants to one of three groups with one group consuming a 
beverage containing 520 milligrams (mg) of cocoa flavanols (CF), a second group 
consuming a beverage containing 994 mg of CF, and a matched control. Results showed 
that the groups who consumed 520 mg of CF and 994 mg of CF significantly improved 
scores on a cognitive battery test 42. In addition, the 994 mg of CF beverage resulted in 
significant improvement in rapid visual information processing 42. Field, Williams, Butler 
43 also studied healthy adult subjects who consumed chocolate containing 720 mg of CF 
and a matched quantity of white chocolate, which served as the control group as white 
chocolate lacks cacao. Researchers found that the flavanol group improved in visual 
contrast sensitivity, reduced the time required to detect motion direction, and improved 
spatial memory 43. Both of these studies noted that while the mechanisms underlying the 
effects are unknown they may be related to effects of CF on endothelial function and 
blood flow which allows improved transfer and delivery of oxygen and nutrients 
systemically. 
Mastroiacovo, Kwik-Uribe, Grassi, Necozione, Raffaele, Pistacchio, Righetti, 
Bocale, Lechiara, Marini, Ferri, Desideri 39 examined elderly subjects who showed 
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clinical evidence of cognitive deficits and had them consume a drink everyday for eight 
weeks with various concentrations of flavanols. One group consumed high flavanols 993 
mg, the intermediate group consumed 520 mg of flavaonol, and the low flavanol group 
consumed 48 mg 39. Results revealed an overall improvement in response time and verbal 
fluency scores in all three groups with greatest improvement being in the highest 
concentration group 39. They also found physiological benefits with improvements in 
insulin resistance, blood pressure, and lipid peroxidation in the high flavanol group and in 
the intermediate flavanol group 39. These results are noteworthy as lipid peroxidation is a 
mechanism of oxidative stress that occurs when free radicals damage the lipid cellular 
membrane and thus destroy the integrity of the cell and its functions.  
Davison, Berry, Misan, Coates, Buckley, Howe 44 aimed to determine a minimum 
dose effect of flavanol rich cocoa products relative to lowering blood pressure in men and 
women with mild untreated hypertension. Participants consumed a daily cocoa beverage 
containing 33, 372, 712 or 1052 mg of cocoa flavanols per day 44. Significant reductions 
were noted only in the 1052 mg/day group, no reduction was seen at any other dose in 
this particular study 44. In another study, Grassi, Desideri, Necozione, di Giosia, 
Barnabei, Allegaert, Bernaert, Ferri 45 examined cocoa flavonoids on cardiovascular 
functions in healthy adults. Total flavanoid concentration ranged from zero mg for the 
control group to 80, 200, 500 and 800mg per day on each week. Compared with controls, 
all cocoa-active treatments significantly and dose-dependently increased flow mediated 
vasodilation 45. Results also showed improvements in arterial stiffness and blood pressure 
during each week of treatment 45. A previously conducted cross sectional study on older 
adults demonstrated a dose response relationship with a flavonoid rich beverage 
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consumption at 10 grams per day for optimal cognitive benefit 46. However, the 
antioxidant concentration and percentage of cacao were not noted or controlled for in this 
study which limits the generalizability of the dose dependent outcomes. Further research 
is still needed to reproduce these effects in similar samples and eventually show a 
consistent dose response. 
A meta-analysis was conducted to evaluate the effect of flavanoid rich cocoa 
(FRC) on cardiovascular risk factors and to assess a dose-response relationship and the 
studies reviewed included samples of healthy, diabetic, overweight, and heart disease 
subjects 47. Results showed that in response to FRC consumption, systolic blood pressure 
decreased, insulin resistance decreased, Low Density Lipoprotein cholesterol decreased, 
flow mediated vasodilation increased, and High Density Lipoprotein cholesterol 
increased 47. A dose-response relationship was found between FRC and flow mediated 
vasodilation with a maximum effect observed at a flavonoid dose of 500 mg/day 47. The 
above literature points to the benefits that cocoa has, particularly, the flavanols and 
flavonoids which are nutritional antioxidants, on a variety of physiological mechanisms.  
Richelle, Tavazzi, Enslen, Offord 48 conducted a study on adult males, both 
smokers and non-smokers, analyzing the peak concentration of epicatechins from blood 
samples following consumption of dark chocolate. Findings from this study suggest that 
epicatechins, a subgroup of polyphenol antioxidants, peak in the blood at approximately 
two hours after 40 grams were consumed and at approximately three hours after 80 grams 
were consumed 48. More recent research echoes these findings that epicatechins, 
antioxidants naturally found in cacao, peak in the blood two to three hours following 
consumption and resume a baseline level six to eight hours later 49,50. In a review article 
 14 
by Vauzour 40, the neurological benefits of polyphenols, including those found in cacao 
are identified as promoting neurogenesis and neurocognitive functions. For example, 
polyphenols have been noted to cross the blood brain barrier in both animal and human 
studies suggesting their neuroprotective features not only to support the antioxidant 
defense against oxidative stress but also in modulating inflammation in the brain 40. Both, 
Richelle, Tavazzi, Enslen, Offord 48 and Vauzour 40, may support the benefit of 
maintaining a certain level of concentration in the bloodstream for physiological and 
neurocognitive benefits. Future studies need to examine the amount of specific dietary 
antioxidants’ and their absorption for dosing recommendations and therapeutic purposes 
in human subjects. 
 
Neurocognitive Benefits of Cacao 
In addition to physiological health benefits noted above, there are also 
neurocognitive benefits to cacao consumption. Berk et al. (2016) found that when healthy 
adults consumed 70% cacao gamma wave frequency was elicited as measured by 
electroencephalogram (EEG) of the brain. Gamma wave frequency (γBA 31–40 Hz) is 
the highest brain frequency associated with long term recall, neural synchronization, 
learning, and heightened meditation (Berk et al., 2016). In a follow up study, they found 
similar results in healthy adults who consumed 70% cacao with nine cerebral cortical 
EEG leads to measure brain activity which again produced gamma wave frequencies 
(γBA 31–40 Hz) (Berk et al., 2017).  
Furthermore, gamma frequency has been studied in both animal and human 
models and findings support that this high-level frequency is associated with short term 
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memory, long term memory, enhanced neuronal communication and synchronization 51. 
The rapidity of gamma wave frequencies results in firing of the tight and rhythmic 
oscillations of the neuron thus allowing for faster interneural communication 51. This 
research suggests both the neuroprotective and neuromodulatory benefits of high 
antioxidant cacao on brain health. Gamma frequency also plays a role in working 
memory, memory retrieval, and attention skills 52. Future studies will need to identify if 
these changes in brain wave frequency carryover to attention and task performance on 
participants with neurocognitive disorders. The aforementioned studies point to the 
critical and valuable role that gamma wave frequencies play in higher cognitive 
processing skills which would be advantageous for the ASD population.  
The above literature repeatedly points to both the health and physiological 
benefits of cacao on adults. To date, to the author’s knowledge, only one study has 
looked at potential health benefits of cacao on children. Children with idiopathic 
constipation between the ages of three and six consumed four grams of cocoa husk per 
day and children between the ages of seven and 10 consumed eight grams per day 53. The 
children who received cocoa husk supplements tended to increase the number of bowel 
movements compared to the placebo group 53. Although this study was not related to 
ASD, nor to the concentration of cacao or flavanols, it shows limited evidence on health 
benefits of cacao for children. 
  
Antioxidants, Autism, and Behavior 
In the ASD population, five studies have been conducted looking at an 
antioxidant intervention relative to behavior change. According to the first identified 
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study of its kind, researchers examined use of high antioxidant vitamin C providing eight 
grams per 70 kilograms per day for 30 weeks and found a reduction in symptom severity 
54. This study examined antioxidants’ potential benefit to children with ASD. In 2013, 
Ghanizadeh and Moghimi-Sarani, studied children between the ages of three and a half 
and 16 and the children were randomly assigned to one of two groups. One group 
received N-Acetylcysteine (NAC) (1200 mg/day) plus risperidone and the other received 
placebo plus risperidone 55. N-Acetylcysteine is an antioxidant pro-drug and a precursor 
to arguably the most important antioxidant, glutathione. Results showed a significant 
improvement in irritability in the NAC group on the Aberrant Behavior Checklist 55.  
More recently, researchers examined children between four and 12 years of age 
where one group received risperidone plus NAC and the control group received 
risperidone plus a placebo 56. The dose of NAC ranged from 600 to 900 mg/day 56. 
Results showed a significant improvement in both irritability and 
hyperactivity/noncompliance subscales on the Aberrant Behavior Checklist 56. The most 
common noted adverse effects in the NAC plus risperidone group were constipation, 
increased appetite, fatigue, nervousness, and daytime drowsiness 55,56.  
Lastly, a recent pilot study assessed NAC in children with ASD between ages 
three and 12 35. Subjects were randomized to the NAC or control group and were initiated 
at 900mg/daily for four weeks, then 900 mg twice daily for four weeks, and 900 mg three 
times daily for four weeks 35. Follow-up data revealed that the NAC group showed 
significant improvements on the Aberrant Behavior Checklist irritability subscale 
compared to the control group 35. Also, stereotypy behaviors improved on the repetitive 
behavior scale and social cognition improved on one of the subtests on the social 
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responsiveness scale 35. These studies are key in showing some of the reproducible 
evidence of potential therapeutic effects and improved behavioral outcomes following 
antioxidant interventions in children with ASD. 
  
Significance of the Present Study 
Traditional behavioral interventions for ASD, although valuable, are missing a 
holistic approach as they typically do not target the physiological components to 
neurocognitive deficits related to oxidative stress. The antioxidant and free radical 
imbalance in ASD may require the combination of traditional therapies and nutritional 
interventions to complement each other for optimal outcomes and quality of life for 
children and families living with ASD. To date, to the author’s knowledge, previous 
literature has not examined the potential association between antioxidant rich foods, such 
as cacao, and ASD behaviors. However, based on the literature reviewed, oxidative stress 
markers, such as free radicals, are elevated in children with ASD and thus can be reduced 
by high antioxidant consumption, specifically cacao. Thus, the purpose of the study was 
to provide information on the relationship between consuming high antioxidant cacao and 
behavior in children with ASD. Specifically, this study aimed to examine the following 
research questions:  
1. What is the impact of consuming high antioxidant cacao on the severity of 
Autistic behaviors? 
2. What is the parents’ perspective on their child’s Autistic behaviors following 
cacao consumption? 
3.  What is the teachers’ perspective on their Autistic student’s behaviors following 
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cacao consumption? 
4.  What is the impact on parental stress following the cacao consumption 
intervention? 
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CHAPTER 2 
ANTIOXIDANTS AND AUTISM: TEACHERS’ PERCEPTIONS OF 
BEHAVIORAL CHANGES 
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Abstract 
 BACKGROUND- Children with Autism Spectrum Disorder (ASD) demonstrate 
a physiological imbalance between free radicals, resultant from oxidative stress, and 
antioxidants. Oxidative stress is linked to the pathogenesis of this neurocognitive 
disorder. The aim of this pilot feasibility study was to examine the effect of consumption 
of high concentration antioxidant cacao on behavior of children with ASD.  
 METHODS- This was a 4-week pre-test post-test experimental pilot study of 
high antioxidant cacao and children with ASD. Participants consumed 8 squares (or 16 
grams) per day of the dark chocolate which had a concentration of 70% cacao and 30% 
organic cane sugar (total antioxidant concentration was 8,320). The two main behavioral 
measures were the Aberrant Behavior Checklist- 2nd Edition and the Autism Spectrum 
Rating Scale which were completed by the child’s teacher at baseline and end of week 
four.   
 RESULTS- Sixteen participants were recruited for this study. Follow up data was 
available on 12 participants (9 males, 3 females, mean age of 10.9 ±3.9 years). 
Significant improvements on the Autism Spectrum Rating Scale were noted in 
Social/Communication (p=0.03, η2=0.79), Unusual Behaviors (p=0.02, η2=0.70), and 
Self-Regulation (p=0.04, η2=0.59). No significant changes were noted on any of the 
Aberrant Behavior Checklist-2 subscales (p>.05). 
 CONCLUSION- Results from this study support the potential therapeutic benefit 
of antioxidants in improving social communication, unusual behaviors, and self-
regulation behaviors of children with ASD. Further robust randomized controlled trials 
are now necessary to elaborate the validity of these findings.  
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complementary therapies 
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Introduction 
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized 
by deficits in social and communication skills, functional impairments across multiple 
settings, repetitive and atypical behaviors, as well as self-regulation impairments related 
to sensory input from the environment  (APA, 2013). According to the Center for Disease 
Control and Prevention (CDC), one in 68 children are identified as having ASD with it 
being 4.5 times more prevalent in males than females  (CDC, 2016). Although the 
specific etiology of ASD remains elusive, there are genetic, environmental, 
immunological, and oxidative stress influences that are related to the pathogenesis of the 
disorder 3,4. Therefore, the complexity and broad spectrum of ASD lends itself to the need 
for a variety of interventions and therapies for these children.  
Behavioral therapists, speech and language pathologists, and occupational 
therapists often work in parallel in both educational and medical settings to provide 
therapy for children with ASD 17. Children with ASD often receive these services through 
their special education program. Furthermore, it should be noted that both special 
education and general education teachers educate students with ASD 10. Evidence based 
practices are limited in nature for the ASD population due to the heterogeneous profiles 
of the disorder and often times practitioners implement a variety of strategies that have 
not been studied in combination 11. Additional barriers for educators and practitioners 
include the child’s behaviors which make conducting standardized assessments 
challenging to accurately develop goals and treatment plans in the school environment 12. 
Overall, there is limited evidence on teachers’ perceptions of ASD behaviors in the 
classroom setting.  
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The Food and Drug Administration approved two pharmaceutical agents for ASD, 
Risperdal and Abilify. Both drugs target maladaptive behaviors and irritability 14,15. In 
addition, almost one third of the ASD population are on Selective Serotonin Reuptake 
Inhibitor (SSRIs) 14. However, as with any drug, there are associated adverse effects that 
include increased appetite, weight gain, dizziness, drooling, drowsiness, fatigue, 
vomiting, nasopharyngitis, fever, insomnia, and upper respiratory infections 14,16. Thus, 
non-pharmacological lifestyle oriented interventions may compliment traditional 
therapies in targeting behavior, mood, and performance issues associated with ASD 
without side effects of medication 17. 
Due to the heterogeneous nature of ASD severity and behaviors, which can 
change over the course of natural development, it is common to see this population 
utilizing multiple therapeutic interventions through the medical model, education system, 
and through alternative therapies. Common types of CAM used with ASD children 
include but are not limited to diet modifications, vitamin and supplement use, digestive 
enzymes, music therapy, among others. Complementary and alternative medicine (CAM) 
among children and adolescents are often used to address both behavioral and emotional 
issues, such as those found in children with ASD 58. Families of children with ASD 
typically use CAM therapies and treatments when their child has multiple conditions 59,60. 
Parents often use CAM with their ASD children to target the symptomology of mood and 
behavior disturbances related to hyperactivity, irritability, and attention skills 60. 
Pharmacologically there are only the two aforementioned approved medications for ASD 
and thus any other medications prescribed are used to address behaviors related to 
maladaptive behaviors, mood, hyperactivity, and the like 61. Thus, there is a need for 
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CAM interventions to offset potential adverse effects of pharmaceutical agents while still 
targeting some of the core symptoms.  
Although the etiology of ASD is multifactorial, research suggests that there are 
some neurophysiological differences between individuals with and without ASD 24.  For 
example, irregularities in neuronal connections have been associated with “cognitive, 
social, and sensory behavioral symptoms,” 24. Of particular relevance to the current study 
is research on oxidative stress and ASD symptomology. Previous research indicated a 
significant increase in oxidative stress markers in children with ASD compared to 
matched controls and their non-Autistic siblings 3,20. Furthermore, the severity of autistic 
behaviors was positively correlated with oxidative stress markers, whereas antioxidant 
levels were negatively correlated with autistic behaviors 3,26. 
Oxidative stress can be due to mitochondrial impairment, environmental factors, 
metabolic issues, and genetic predisposition in ASD 20. In turn, oxidative stress can also 
lead to a cascade of events such as inflammation, damage to cell membranes, 
autoimmunity, methylation damage, cell death, and neurological impairments 26. Thus, it 
is evident that this lack of sufficient antioxidants creates a plethora of detrimental 
physiological outcomes which can contribute to the pathogenesis of ASD. 
The human body offers natural intrinsic mechanisms to counter the damaging 
effects of free radicals that lead to oxidative stress by producing antioxidants 
endogenously by the body 19,62. Oxidative stress biomarkers are particularly noteworthy 
as they have the potential to be modulated by means of non-pharmacological 
interventions, such as nutritional interventions 29. Antioxidants’ benefits include 
improvement of cellular structure, neutralizing free radicals, neuroprotective, anti-
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inflammatory, accumulation in the hippocampus and cortex, and improvement of 
vascular endothelial function 27,32.  
In the ASD population, several key studies have been conducted looking at 
antioxidant intervention relative to behavior change. According to the first identified 
study of its kind, researchers examined use of high antioxidant vitamin C providing eight 
grams per 70 kilograms per day for 30 weeks and found a reduction in symptom severity 
54. In addition, several randomized trials using N-Acetylcysteine (NAC), an antioxidant 
pro-drug, intervention reported significant improvements in irritability, and 
hyperactivity/noncompliance subscales on the Aberrant Behavior Checklist (ABC) 35,55,56. 
Cacao is a natural and potent antioxidant and is a food rich in flavonoids and their 
sub group flavanols. For the purposes of this paper, cacao and cocoa are used 
interchangeably. Both flavonoids and flavanols are associated with improved cognitive 
processing, alertness, and processing speed 37. Known physiological benefits of cocoa 
include improved cardiovascular activity, insulin resistance, blood pressure, endothelial 
function, lipid peroxidataion, cognitive response time, enhanced gamma frequency, and 
increased cerebral blood flow 27,32,37-39. The aforementioned studies summarize the 
inherent value in cacao as a natural superfood for the mind and the body. 
The purpose of this study was to examine changes in ASD children’s behavior 
following 70% cacao consumption, with a high total antioxidant concentration, over a 
four-week period. Changes in behavior were assessed using two behavior scales: ABC-2 
and Autism Spectrum Rating Scale (ASRS) 63,64.  
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Methods 
Study Design 
This was a four-week pre-test post-test experimental clinical trial of children with 
ASD who consumed high antioxidant cacao, also known as dark chocolate. The study 
was conducted in Southern California, United States of America between September 
2017 and March 2018. Participants were recruited through snowball sampling techniques 
following study approval. This study was approved by the Institutional Review Board at 
Loma Linda University and registered in the National Institutes of Health online database 
at clinicaltrials.gov (NCT 03195465). Additionally, an Investigational New Drug 
application was submitted, however, the application was not deemed mandatory for this 
study by the Food and Drug Administration. 
  
Participants 
Participants were children with a diagnosis of ASD between the ages of 4 and 18 
and their classroom teachers. Sixteen children and their teachers, from 13 different school 
districts in Southern California, were recruited. Two teacher participants were excluded 
from the analysis due to missing study data, one was not able to provide post-intervention 
feedback because of a school break, and one was excluded because the child was home 
schooled thus there was no teacher rater available. For subjects’ characteristics, refer to 
Table 1. 
In order to be eligible for the study, participants had to have a clinical diagnosis of 
Autism Spectrum Disorder, be between the ages of four and 18, and like eating dark 
chocolate. A taste test was offered to the child at baseline to ensure he/she would be 
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willing to eat it daily for four weeks. Participants with food allergies, caffeine 
hypersensitivity, theobromine hypersensitivity, a history of seizures or epilepsy, a 
developmental age less than 24 months, diabetes, and those who were currently enrolled 
in another study were excluded from this study. 
  
Procedures and Interventions 
The cacao utilized in this study was analyzed for total antioxidant activity at 
Medallion Laboratories in Minnesota. They are considered to be a premiere and 
accredited nutraceutical lab that uses scientifically sound analyses on food, dietary 
supplements, and pharmaceutical agents. The standardized unit of analysis for total 
antioxidant activity is measured in µmoles trolox equivalent (TE) / 100 grams (g) 30. The 
antioxidant activity of the cacao used was 52,000 µmoles TE / 100 g. The dark chocolate 
used in this study consisted of two ingredients, 70% cacao and 30% organic cane sugar. 
Participants in the study consumed eight squares of the dark chocolate, or 16 grams per 
day totaling 8,320 µmoles TE / 100 grams. Participants consumed four squares of the 
cacao twice daily with the first dose in the morning and the second dose in the afternoon.  
Participants consumed their first dose at approximately 8:00 a.m. and their second dose at 
approximately 6:00 p.m. depending on the child’s school and sleep schedule. All 
participants were asked to be consistent at both times of day for the duration of the study 
and logs were kept and collected each week to check for compliance. The cacao was 
wrapped in foil, parchment paper, and sealed Ziploc bags to protect it from light and air 
so as to prevent oxidation in order to maintain the cacao's antioxidant integrity.  
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Measures 
The primary outcome measures were the standardized assessment scales: 
Aberrant Behavior Checklist 2nd Edition (ABC-2) and the Autism Spectrum Rating Scale 
(ASRS). Both scales have been validated and are used to assess behavioral outcomes in 
children with ASD 63-65.  
The ABC-2 scale consists of five sub-scales which include measures of 
Irritability, Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance, and 
Inappropriate Speech. The ABC-2 consists of 58 questions with each question ranging 
from zero to three; 0 = no problem, 1 = the behavior is not a problem but slight in degree, 
2 = the problem is moderately serious, and 3 = the problem is severe in degree 63,66. The 
sum of each subscale was calculated and larger subscale totals indicated more severe 
behaviors in that category. 
The ASRS consists of three subscales which include Social/Communication, 
Unusual Behaviors, and Self-Regulation for six to 18 year olds and 
Social/Communication and Unusual Behaviors for two to five year olds. The ASRS 
consists of 71 questions, with each question ranging from zero to four; 0 = behavior never 
happens, 1 = rarely happens, 2 = occasionally happens, 3 = frequently happens, and 4 = 
happens very frequently. In other words, the higher the score the more severe the 
behaviors for each subscale. Scores from each subscale were calculated using T-Scores in 
accordance with the standard scoring technique 64. Teachers filled out both questionnaires 
(ABC-2 & ASRS) at baseline and at the end of week four. 
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Statistical Analyses 
A sample size of 15 subjects was estimated using a medium effect size of 0.70, a 
power of 0.80, and a level of significance set at 0.05. Data analysis was performed using 
IBM SPSS Statistics Version 25.0. Data was summarized using mean ± standard 
deviation for quantitative variables and frequency (%) for categorical variables. The 
normality of the outcome variables was examined using Shapiro-Wilk test. Wilcoxon 
Signed Rank Test was conducted to compare changes (baseline vs. four weeks later) in 
ABC-2 and ASRS scores. Results were considered significant at p ≤ 0.05. 
 
Results 
Participant characteristics are reported in Table 1.  Twelve children with ASD 
with a mean age of 10.9 ± 3.9 participated in the study. Seventy five percent were males 
(n = 9) and 42% were White (n = 5). Fifty eight percent of the participants were in a 
special day class (n = 7) and seventy five percent were verbal (n = 9). All the participants 
were enrolled in an Individualized Education Program. (Table 1)  
Child’s medical history and type of therapy are displayed in Table 2. Seventy five 
percent of participants had some type of stressful event (parent divorced, changed 
schools, parent changed job, family moved, death in family, financial problems). 
Approximately 83% sleep, on average, seven or more hours per night. The majority of 
the participants either previously received or currently receive speech therapy, 
occupational therapy, and applied behavioral analysis. (Table 2) 
Changes in ABC-2 and ASRS scores are reported in Table 3. There were no 
significant changes in the ABC-2 subscales of Irritability, Social Withdrawal, Stereotypic 
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Behavior, Hyperactivity/Noncompliance, and Inappropriate Speech (p >.05). A 
significant improvement was noted in Social/Communication (p=0.03, η2=0.79), Unusual 
Behaviors (p=0.02, η2=0.70), and Self-Regulation (p=0.04, η2=0.59). (Table 3) 
 
Discussion 
In this pilot study, we conducted a pre-test post-test experimental clinical trial to 
examine the effects of high antioxidant cacao consumption on behaviors in children with 
ASD. Teacher perceptions were recorded as rated on the ABC-2 and ASRS at the 
beginning and end of the four-week study. The cacao intervention was well tolerated and 
no side effects were reported by any of the participants’ parents over the course of the 
intervention. The results of this study indicated that teachers perceived a significant 
improvement in their ASD student’s behavior in the ASRS subcategories of: 1) 
social/communication, 2) unusual behaviors, and 3) self-regulation. No significant 
changes were noted on any of the subscales on the ABC-2. This is particularly 
noteworthy as previous antioxidant and ASD studies used the ABC scale and found 
improvements in hyperactivity and irritability subscales 35,55,56. A possible explanation for 
the difference between the aforementioned studies and this study may be attributed to the 
fact that the teacher was the informant since they are trained in objective assessments, 
whereas in previous studies a trained rater was the informant. Another possible 
explanation could be due to the different time frames used in previous studies conducted 
for eight weeks, 10 weeks, 12 weeks and 30 weeks compared to four weeks in the present 
study 35,54-56. These investigations suggest the potential behavioral benefits of antioxidant 
therapies on ASD as a neurocognitive disorder 35,55,56.  
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The effects of antioxidants on behavior and mood in children with ASD is not 
well understood and the research is still in its infancy. However, based on the results 
from previous literature in adults, the evidence on cocoa appears promising in its 
neuroprotective benefits. For example, flavonoids, a subclass of flavanols found in cacao, 
have the ability to cross the blood brain barrier which demonstrates their neuroprotective 
mechanisms as well as their role in cognitive functions such as learning and memory 34. 
Further, consumption of cocoa flavanols (CF) in adults significantly improved scores on 
a cognitive battery test and in rapid visual information processing, visual contrast 
sensitivity, reduced the time required to detect motion direction, and improved spatial 
memory 42,43. Both of these studies noted that while the mechanisms underlying the 
effects are still unknown and they may be related to effects of CF on endothelial function 
and blood flow which allows improved transfer and delivery of oxygen and nutrients 
systemically. In a recent brief review, researchers concluded that consumption of CF 
demonstrated improvements in cognitive performance, working memory, attention, 
neuroprotective mechanisms, and processing speed 67. The aforementioned studies were 
conducted on adult populations including cognitively at risk adults, however, no studies 
have been done on school-aged children with ASD 34,42,43,67.  
This study had some limitations that include a lack of control group and limited 
sample size. Additionally, investigators did not monitor overall nutritional intake 
throughout the entirety of the study which means potential confounders in diet could have 
impacted validity. The length of the study may have not been sufficient to demonstrate 
more significant behavior change in the participants. Due to the pilot feasibility nature of 
this study, it was premature to include different intake concentrations of cacao for 
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participants as previous literature on adults was inconsistent and limited. All participants 
were receiving some form of therapy targeting behavior, communication, and regulation 
skills, however, it would be unethical and unrealistic to include ASD children who were 
not receiving any type of therapy. 
Future studies are recommended so as to conduct an intervention for extended 
periods of time and assess changes at multiple time points. Considering analyzing 
biomarkers such as, urine or serum blood samples would be supportive and help validate 
any physiological changes in antioxidant and free radical status. Comparing different 
groups with different amounts of cacao, as well as running a randomized control trial will 
help determine if the change was in fact due to the intervention 17. Additionally, 
examining behavior changes both through informant based psychometric assessments and 
performance based assessments (i.e. motor based tasks, attention tasks) would increase 
validity of this novel intervention. Complementary and alternative medicine, or therapies, 
are worth examining in the ASD population with consideration of the child’s medical 
history, diet history, and efficacy of alternative therapies before their use is recommended 
61. Additionally, biologically based therapies, such as nutrition, are often used as parents 
tend to use CAM intervention in an effort to avoid the adverse effects of pharmaceutical 
agents 68. Thus, nutrition interventions, such as this study, should continue to be analyzed 
as a CAM for the ASD population. 
  
Conclusion 
To the authors’ knowledge, to date, this is the first pilot study linking nutritional 
antioxidant cacao consumption to behavior in the ASD population from a teacher’s 
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perspective. Results from this study support the potential therapeutic benefit of 
antioxidants in improving behaviors of children with ASD. Additional robust randomized 
controlled trials are needed to further examine and validate these positive outcomes. 
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Table 1. Participant characteristics (N = 12). 
 n % 
Age (Mean ± SD) 10.9 ± 3.9  
 
Gender  
Female 
Male 
 
 
3 
9 
 
 
25.0 
75.0 
 
Grade 
K 
1 
2 
4 
5 
6 
10 
12 
 
 
1 
1 
1 
1 
2 
3 
2 
1 
 
 
  8.3 
  8.3 
  8.3 
  8.3 
16.7 
25.0 
16.7 
  8.3 
 
Class setting 
SDC Mild/Moderate 
SDC Moderate/Severe 
General Education with RSP 
General education full inclusion 
 
 
6 
1 
2 
3 
 
 
50.0 
  8.3 
16.6 
25.0 
 
IEP 12 100.0 
 
Verbal ability 
Non verbal 
Limited verbal 
Verbal 
 
 
1 
2 
9 
 
 
  8.3 
16.7 
75.0 
 
Ethnicity  
White 
Hispanic or Latino 
African American 
Mixed ethnicities 
 
 
5 
3 
1 
3 
 
 
41.7 
25.0 
  8.3 
25.0 
*Abbreviations: SDC, Special Day Class; IEP, Individualized Education Program; RSP, 
Resource Specialist Program  
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Table 2. Child’s medical history and type of therapy (N=12). 
 n % 
Stressful Event 
None 
Parent divorced/separated 
Parent changed jobs 
Parent changed job/changed schools 
Family moved/financial problems 
Family moved/changed schools 
Death in family/parent changed job/changed schools 
 
 
3 
1 
2 
1 
1 
2 
1 
 
25.0 
  8.3 
16.7 
  8.3 
  8.3 
16.7 
  8.3 
Headaches 1   8.3 
 
ADHD 
 
4 33.3 
Anxiety/Depression 2 
 
16.7 
Hours of sleep per day 
4-6 hours 
7-8 hours 
9 hours or more 
 
1 
5 
5 
 
  8.3 
41.7 
41.7 
 
Medications 
ADHD 
ADD 
Anxiety 
Mood Disorder 
 
 
3 
1 
2 
1 
 
 
25.0 
  8.3 
16.7 
  8.3 
 
Type of Therapy 
Individual psychotherapy 
 
 
1 
 
 
  8.3 
Group psychotherapy 1   8.3 
Family therapy 1   8.3 
Speech therapy 11 91.7 
Occupational therapy  10 83.3 
Applied Behavior Analysis 8 66.7 
Physical therapy 3 25.0 
Early intervention 8 66.7 
Abbreviations: ADHD, Attention Deficit Hyperactivity Disorder; ADD, Attention Deficit 
Disorder 
  
 41 
Table 3. Median (min, max) Scores for ABC-2 and ASRS over time. 
Scale Baseline Four weeks p value* (η2) 
ABC-2    
Irritability   5.0 (0,31) 6.0 (0,28) 0.27 (0.18) 
Social Withdrawal 13.5 (1,33) 9.0 (0,32) 0.48 (0.13) 
Stereotypic Behavior   2.5 (0,15) 3.0 (0,15) 0.61 (0.05) 
Hyperactivity/Noncompliance 10.5 (1,36) 8.0 (0,43) 0.20 (0.13) 
Inappropriate Speech   1.0 (0,9) 0.5 (0,9) 0.59 (0.04) 
 
ASRS 
   
Social/Communication 63.0 (55,82) 58.5 (47,82) 0.03 (0.79) 
Unusual Behaviors 66.5 (58,85) 60.5 (53,81) 0.02 (0. 70) 
Self-Regulation 61.0 (51,80) 58.0 (43,83) 0.04 (0.59) 
Total of all 3 Subscales T Score 69.5 (62,79) 59.0 (52,79) 0.007 (1.4) 
Abbreviations: ABC-2, Aberrant Behavior Checklist 2nd Edition; ASRS, Autism 
Spectrum Rating Scale, η2 = effect size 
*Wilcoxon Signed Rank Test 
 Effect Size = mean of difference 
                       SD of the difference 
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Abstract 
BACKGROUND- Children with Autism Spectrum Disorder (ASD) tend to have 
higher free radicals than antioxidants compared to their matched controls. The aim of this 
pilot study was to examine the effect of high antioxidant cacao consumption on behavior 
in children with ASD. 
METHODS- This was a 4-week repeated measures experimental study. Sixteen 
participants, aged 4 to 17 years, consumed 8 squares of dark chocolate per day. The 
Aberrant Behavior Checklist- 2nd Edition (ABC-2) and the Autism Spectrum Rating Scale 
(ASRS), were completed by the parent at baseline, end of week two, and end of week 
four.  
RESULTS- Significant improvements were noted on the ABC-2 subscales of 
Irritability, Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance, and 
Inappropriate Speech (p≤0.05) and on the ASRS scales (p≤0.05). 
CONCLUSION- Results indicated that antioxidant intake can improve behaviors 
of ASD children. More studies are needed to validate these findings.  
 ClinicalTrials.gov Identifier- NCT 03195465 
 Key words: antioxidants, cacao, autism, behavior, parents, perceptions 
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Introduction 
 
Autism Spectrum Disorder 
Autism Spectrum Disorder (ASD) is a life-long neurodevelopmental disorder 
characterized by core deficits in communication skills, maladaptive behaviors, and self-
regulation impairments related to atypical responses to sensory stimuli in the 
environment (APA, 2013). The prevalence of ASD in the United States (U.S.) is reported 
at 1 in 68 children with it being four times more common in males than females (CDC, 
2016). According to the World Health Organization (2017), worldwide, one in 160 
children have ASD. The etiology of ASD is still unknown, however, genetic, 
environmental, immunological, and oxidative stress factors are linked to its pathogenesis 
3,4.  Additionally, perinatal and neonatal risk factors such as, “abnormal fetal presentation, 
umbilical-cord complications, fetal distress, birth injury or trauma, multiple birth, 
maternal hemorrhage, summer birth, low birth weight, small for gestational age,” among 
others have been identified as part of the association with ASD 5. The heterogeneity of 
ASD lends itself to the need for a variety of interventions, both traditional and non-
traditional, as no one therapy works across the spectrum. 
  
Conventional Therapies 
Occupational therapists, speech therapists, and behavioral therapists are the most 
common professionals that work with children with ASD. Occupational therapists 
address self-regulation as it relates to sensory dysfunction in the classroom, transitions 
between environments, and for task completion in home and school environments 9. 
Speech and Language Pathologists work on social interaction, communication skills, and 
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alternative communication techniques, among other speech related impediments to 
enhance communication (American Speech-Language-Hearing Association, 2006). 
Behavioral therapists work with ASD children on aberrant behaviors, language skills, 
daily living skills, and social functioning. Applied behavioral analysis (ABA), employs 
rote discrete trials in a one on one setting and is an intensive approach that is 
recommended up to 40 hours per week 6,7. All three of these intervention approaches are 
used in parallel to address ASD children’s performance skills and behavior in both 
educational and home environments.  
Currently, there are only two Food & Drug Administration (FDA) approved drugs 
for ASD, Risperidone and Abilify 14. Risperidone is a second-generation antipsychotic 
prescribed for maladaptive behaviors and self-injurious behaviors whereas Abilify treats 
mood and irritability 14. Adverse effects include weight gain, dizziness, drooling, fatigue, 
vomiting, nasopharyngitis, fever, insomnia, and upper respiratory infections 14,16. Thus, 
there is both a place and need for complementary and alternative therapies in addressing 
the behavioral symptomology of ASD that impedes on quality of life without some of the 
adverse effects of pharmacological agents.  
When the aforementioned therapies and pharmaceutical agents are considered, the 
cost of ASD becomes colossal. A recent study reported that the cost of ASD in the United 
States (U.S.), across one’s lifetime, is $1.4 million and $2.4 million, respectively, if they 
also have an intellectual disability 18. However, as with any disability or disorder the cost 
is indefinite as there are also psychological and stress costs that cannot be quantified for 
the individuals or families caring for them. Lifestyle oriented approaches may, then, be 
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necessary not only to potentially offset costs but to improve quality of life in a long term 
sustainable fashion. 
 
Oxidative Stress and ASD 
Even though ASD’s etiology is multifactorial and still unknown, research 
suggests there may be neuron irregularity, between those with and without ASD, that is 
linked to the classic behavioral and social symptoms 24. Oxidative stress, an imbalance 
between antioxidants and free radicals, is of significance to this study and has been linked 
to the pathogenesis of ASD. Damodaran, Arumugam 3 found a significant increase in 
oxidative stress markers in children with ASD compared to matched controls and the 
severity of maladaptive behaviors were positively correlated with free radicals while 
antioxidants were negatively correlated with autistic behaviors 3,26. In addition, elevated 
blood samples of glutathione, glutathione peroxidase, methionine, oxidized glutathione, 
and cysteine have also been found in children with ASD 26. These studies, although 
limited in number, suggest that the excess of free radicals may be linked to adverse 
behavioral outcomes. 
Ming, Stein, Brimacombe, Johnson, Lambert, Wagner 20 suggests that children 
with ASD tend to have greater markers of oxidative stress compared to age matched 
controls or their non-Autistic siblings. Oxidative stress may be related to mitochondrial 
impairment, environmental factors, metabolic issues, and genetic predisposition (Ming et 
al., 2005). Inflammation, damage to cellular membranes, autoimmunity, methylation 
damage, cell death, and neurological impairments are all resultant of free radical damage 
26. Oxidative stress can be identified through markers of antioxidant enzymes, lipid 
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peroxidation, and protein oxidation, all of which are higher in children with autism 
compared to their matched controls 3,20. In summary, the above studies support emerging 
evidence on the physiological differences in oxidative stress between children with ASD 
and those without, creating detrimental biological and behavioral outcomes. 
Our bodies have an innate mechanism to endogenously produce antioxidants to 
counter the deleterious effects of free radicals caused by oxidative stress 19,62. However, 
when these mechanisms are out of balance we may need to consider nutritional options to 
supplement these deficits. Antioxidants benefit us physiologically by maintaining cellular 
integrity, combating free radicals, and improving vascular function while also offering 
neuroprotection by accumulating in the hippocampus and cortex 27,32. As a result, 
antioxidants may be beneficial and necessary to provide homeostasis to oxidative stress 
imbalance, as seen in ASD.  
To date, a few important studies examined the effects of antioxidant intervention 
relative to behavior change in the ASD population. Dolske, Spollen, McKay, Lancashire, 
Tolbert 54 appear to be the first researchers to examine antioxidant therapy, in the form of 
Vitamin C, providing eight grams per 70 kilograms of body weight per day in 500 
milligram (mg) tablets for 30 weeks and found a reduction in autistic symptom severity. 
Additionally, randomized controlled trials using N-Acetylcysteine (NAC), an antioxidant 
pro-drug, intervention found significant improvements in the irritability and 
hyperactivity/noncompliance subscales on the Aberrant Behavior Checklist (ABC) 35,55,56.  
Cacao is a natural and potent antioxidant. For the purposes of this paper, cacao 
and cocoa are used interchangeably. Flavonoids and flavanols, subclasses of antioxidants 
found in cacao, have been correlated with improved cognitive processing, alertness, and 
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processing speed 37. Cocoa’s physiological and neurological benefits are vast and include 
improved cardiovascular activity, insulin resistance, blood pressure, lipid peroxidation, 
enhanced gamma frequency, and increased cerebral blood flow 27,32,37-39. Additionally, 
cocoa protects neurons from apoptosis, promotes angiogenesis, and thus leads to more 
optimal brain functioning which enhances delivery and receipt of oxygen and nutrient 
supply 50. The aforementioned studies summarize the inherent value in cacao as a natural 
functional food for the mind and the body which may be of significant value to 
neurocognitive disorders, such as ASD.  
The purpose of this study was to examine changes in ASD children’s behavior 
following dark chocolate consumption, over a four-week period. Behavioral changes 
were assessed by each child’s parent using two behavior scales: Aberrant Behavior 
Checklist 2nd Edition (ABC-2) and Autism Spectrum Rating Scale (ASRS) 63,64. 
  
Methods 
Study Design 
This was a four-week repeated measures experimental pilot study and clinical trial 
of children with ASD who consumed high antioxidant cacao, or dark chocolate. The 
study was conducted in Southern California, United States of America, between 
September 2017 and March 2018. Recruitment of participants through snowball sampling 
techniques was initiated following study approval. This study was approved by the 
Institutional Review Board at Loma Linda University and was registered in the National 
Institutes of Health online database at clinicaltrials.gov (NCT 03195465). An 
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Investigational New Drug application was submitted to the Food and Drug 
Administration, however, was not required for the study. 
  
Participants 
Participants were children with a diagnosis of ASD, between the ages of 4 and 17, 
and their parents. Seventeen children and their parents were recruited. One participant 
dropped leaving a total sample of sixteen with follow up data. For subjects’ 
characteristics, refer to Table 1. In order to be eligible for the study, participants had to 
have a diagnosis of Autism Spectrum Disorder, be between the ages of four and 18, and 
like eating dark chocolate. A taste test was offered to the child at baseline to ensure 
he/she would be willing to eat it daily for four weeks. Participants with food allergies, 
caffeine hypersensitivity, theobromine hypersensitivity, a history of seizures or epilepsy, 
a developmental age less than 24 months, diabetes, and those who were currently 
enrolled in another study were excluded from this study. 
  
Procedures and Interventions 
The cacao utilized in this study was analyzed for total antioxidant activity at 
Medallion Laboratories in Minnesota. Medallion Labs are considered to be a premiere 
and accredited nutraceutical lab that use scientifically sound analyses on food, dietary 
supplements, and pharmaceutical agents. The standardized unit of analysis for total 
antioxidant activity is measured in µmoles trolox equivalent (TE) / 100 grams (g) 30. The 
antioxidant activity of the cacao used was 52,000 µmoles TE / 100 g. The dark chocolate 
used in this study consisted of two ingredients, 70% cacao and 30% organic cane sugar. 
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Participants in the study consumed eight squares of the dark chocolate, or 16 grams per 
day totaling 8,320 µmoles TE / 100 grams. Participants consumed four squares of the 
cacao twice daily with the first dose in the morning and the second dose in the afternoon, 
or early evening. All participants were asked to be consistent at both times of day for the 
duration of the study and logs were kept and collected each week to assess compliance. 
The cacao was wrapped in parchment paper and foil, then sealed in Ziploc bags to protect 
it from light and air to prevent oxidation in order to maintain the cacao’s antioxidant 
integrity. 
  
Measures 
The primary outcome measures were the Aberrant Behavior Checklist 2nd Edition 
(ABC-2) and the Autism Spectrum Rating Scale (ASRS). Both scales have been 
validated and used to assess behavioral outcomes in children with ASD 63-65.  
The ABC-2 measures behaviors in populations with developmental delays and is 
traditionally administered on children ages five and older, however, permissions were 
obtained from the developer to administer to ages four and older 63. The ABC-2 scale 
consists of five sub-scales including, Irritability, Social Withdrawal, Stereotypic 
Behavior, Hyperactivity/Noncompliance, and Inappropriate Speech. The ABC-2 has 58 
questions with scores ranging from zero to three; 0 = no problem, 1 = the behavior is not 
a problem but slight in degree, 2 = the problem is moderately serious, and 3 = the 
problem is severe in degree 63,66. Subscale sums were calculated and larger subscale totals 
indicated more severe behaviors in that category. 
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The ASRS consists of three scales which include Social/Communication, Unusual 
Behaviors, and Self-Regulation for six to 18 year olds and Social/Communication and 
Unusual Behaviors for two to five year olds. The ASRS has 71 questions, with scores 
ranging from zero to four; 0 = behavior never happens, 1 = rarely happens, 2 = 
occasionally happens, 3 = frequently happens, and 4 = happens very frequently. In other 
words, the higher the score the more severe the behaviors for each scale. Scores from 
each scale were calculated using T-Scores in accordance with the standard scoring 
technique 64. Parents filled out the ABC-2 & ASRS at baseline, end of week two, and end 
of week four. 
 
Statistical Analyses 
A sample size of 15 subjects was estimated using a medium effect size of 0.70, a 
power of 0.80, and a level of significance set at 0.05. Data analysis was performed using 
IBM SPSS for Windows Version 25.0. Data was summarized using mean ± standard 
deviation for quantitative variables and frequency (%) for categorical variables. The 
normality of the outcome variables was examined using Shapiro-Wilk test. Friedman’s 
test was conducted to determine overall change over time. Wilcoxon Signed Rank test 
was used to compare changes between different time points (baseline vs. two weeks; 
baseline vs. four weeks; two weeks vs. four weeks) in ABC-2 and ASRS scores. Results 
were considered significant at p ≤ 0.05. 
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Results 
Participant characteristics are reported in Table 1. Sixteen children with ASD with 
a mean age of 11.1 ± 3.6 participated in the study. Seventy-five percent were males (n = 
12), 31% were White (n = 5), and 25% were Hispanic or Latino (n = 4). A majority of 
participants were enrolled in an Individualized Education Program (n =15, 93.8%) and 
were verbal (n = 11, 68.8%). Forty-four percent of parents worked full time (n = 7), 62% 
had a college degree (n = 10), 62% reported an income of $75,000 or higher (n = 9), and 
81% were married (n = 13). (Table 1)  
Child’s medical history and type of therapy are displayed in Table 2. Twenty-five 
percent of participants had ADHD (n = 4) and were taking medication for attention 
related issues (n = 4). Approximately 56% sleep, on average, seven or more hours per 
night (n = 9). The majority of participants either previously received or were concurrently 
receiving speech therapy, occupational therapy, and applied behavioral analysis. (Table 
2) 
Changes in ABC-2 and ASRS scores are reported in Table 3. Friedman’s test 
results showed there were significant improvements over time in the ABC-2 subscales of 
Irritability (p=.03, η2 = 0.25), Social Withdrawal (p=.01, η2 = 0.29), Stereotypic Behavior 
(p=.05, η2 = 0.13), and Hyperactivity/Noncompliance (p=.04, η2 = 0.20). However, no 
significant difference was noted for Inappropriate Speech (p=.22, η2 = 0.16). Friedman’s 
test also showed a significant improvement in all ASRS subscales including 
Social/Communication (p=.04, η2 = 0.25), Unusual Behaviors (p=.003, η2 = 0.20), Self-
Regulation (p=0.02, η2=0.32), and Total Scores (p<.001, η2=0.54). (Table 3) 
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Post-hoc comparisons revealed that there was a significant difference in 
Irritability between baseline and week four (p =0.035) and between week two and week 
four (p=0.014). For Social Withdrawal, a significant difference was found between 
baseline and week two (p=0.03) and baseline and week four (p=0.023). A significant 
difference was found in Stereotypic Behavior between baseline and week four (p=0.05) 
and between week two and week four (p=0.04). Finally, there was a significant 
improvement in median Hyperactivity/Noncompliance scores between baseline and week 
four (p=0.035). No significant difference was found in median scores for Inappropriate 
Speech over time (p=0.22).  
In terms of ASRS scales, a significant difference was found in 
Social/Communication between baseline and week two (p =0.009) and between baseline 
and week four (p =0.026). A significant difference was found in Unusual Behaviors 
between baseline and week two (p = 0.022) and baseline and week four (p =0.001). There 
was a significant difference in Self-Regulation between baseline and week two (p=0.018) 
and baseline and week four (p=0.012). Overall, there was a significant difference in 
median Total scores on the ASRS between baseline and week two (p=0.002), baseline 
and week four (p=0.002), and between week two and week four (p=0.02). (Table 3) 
 
Discussion 
In this pilot study, a repeated measures experimental clinical trial was conducted 
to examine the effects of high antioxidant cacao consumption on behaviors in children 
with ASD. Overall, participant characteristics revealed that parents were well educated, 
of an above average socioeconomic status, and children came from a stable home as most 
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were married. A previous study indicated that parents of children with ASD, who are 
more educated and affluent, tend to try alternative therapies and enroll their children in 
clinical trials more than others 70.  
Based on parental report, the dark chocolate was well tolerated and no allergic 
reactions were reported over the course of the intervention. The results of this study 
indicated that parents perceived a significant improvement in their ASD child’s behavior 
in the ASRS scales of: 1) Social/Communication, 2) Unusual Behaviors, and 3) Self-
Regulation. Significant improvements were also noted on the ABC-2 subscales of 1) 
Irritability, 2) Social Withdrawal, 3) Stereotypic Behavior, and 4) 
Hyperactivity/Noncompliance. Overall, median scores decreased, indicating that 
participants were less irritable, socially withdrawn, and reduced stereotypic behaviors. In 
addition, participants improved in their social/communication skills and self-regulation, 
and had less unusual behaviors. The results of this study are consistent with the findings 
from the NAC and ASD studies that found improvements in hyperactivity and irritability 
ABC-2 subscales 35,55,56. Based on these studies, there is promising benefit of antioxidant-
based therapies in targeting common behavioral symptoms in ASD 35,55,56.  
Although there is limited research on antioxidants, specifically cacao, and the 
autistic population, previous literature on adults suggests the neuroprotective benefits of 
cacao. In recent reviews, the benefits of the cocoa bean and its derivatives were 
associated with improved cerebrovascular function, permeation of the blood brain barrier 
via flavanols’ (epicatechin and catechin), working memory, attention, processing speed, 
and learning 50,67. Furthermore, ingestion of cocoa flavanols (CF) in adults significantly 
improved cognitive scores, visual information processing, visual contrast sensitivity, and 
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spatial memory 34,42,43. The above studies acknowledge that the underlying mechanisms 
of cocoa on brain health are still under investigation, however, observed benefits may be 
related to effects on endothelial function and blood flow which promote oxygen and 
nutrient delivery systemically. Although the research available on cocoa’s physiological 
and neurological benefit for adults is useful there is still a gap in the literature on how 
cocoa can be used in the pediatric population, specifically those with neurocognitive 
disorders.  
Our study had some limitations. First, a lack of control group limits the 
generalizability of these results. Second, our assessments, although validated and reliable, 
were self-report measures which may include biases. However, previous research 
suggests the impact that ASD behaviors have on the parent and so their observations of 
behavior change may be most accurate as they understand the intricacies of their child’s 
maladaptive behaviors 13. Behaviors associated with ASD not only affect the parent child 
dynamic but also dually stress both the parent and child individually 13. Additionally, 
parents may be strong raters because their stress has been correlated with the severity of 
their child’s behaviors so if behaviors are more or less severe they would be directly 
impacted and thus able to report changes 71. Thirdly, nutritional intake was not monitored 
over the course of the study which means dietary confounders could have impacted 
results. In an attempt to control for dietary effects, we avoided starting participants near 
major holiday breaks, such as Christmas and Thanksgiving, where diet may change more 
drastically. Fourth, the study length may not have been enough to show more significant 
behavior change in the participants. Previous antioxidant studies used different study 
lengths ranging from eight weeks, 10 weeks, 12 weeks, and up to 30 weeks compared to 
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four weeks in the present study 35,54-56. The results of this study demonstrated an overall 
improvement in four of five ABC-2 subscales and all three ASRS scales with the most 
significant changes being after two weeks of intervention. Without a control group, it is 
difficult to rule out the potential for a placebo effect. However, some of the non-
significant findings between baseline and week two strengthens the interpretation of 
results by suggesting that the significant effects observed after two weeks may not simply 
be driven by parents’ belief but an actual intervention effect on behavior. 
A major strength of the present study was the low attrition rate since only one 
participant withdrew from the study. Previous antioxidant and ASD studies did not 
mention total antioxidant activity of interventions used nor was amount of NAC based on 
anthropometric assessments of individual participants 35,54-56. Thus, another strength of 
the present investigation is the analysis and report of total antioxidant activity of the 
cacao validating its use as an antioxidant intervention. It should be noted that because this 
was a pilot feasibility study, it seemed premature to include different intake 
concentrations of cacao for participants as previous literature on adults was inconsistent 
and limited. However, future studies may want to consider offering different 
concentrations based on body weight as nutritional needs differ across the lifespan. All 
participants were receiving one or more traditional therapies targeting core symptoms, 
however, it would be unethical and unrealistic to include ASD children who were not 
receiving any type of therapy.  
Future studies are recommended to run the intervention for longer time periods 
and measure changes throughout the study to determine when the effect occurs. Analysis 
of biomarkers including urine or serum blood samples will be imperative to determine 
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any physiological changes in oxidative stress status. Comparing groups using different 
concentrations of cacao based on anthropometric assessments, such as weight, through 
randomized controlled trials will further validate if observed changes are in fact due to 
the antioxidant intervention. Complementary and alternative medicine (CAM) need to be 
researched to determine efficacious approaches in the ASD population with consideration 
of the child’s medical history and diet history before recommendations can be made 61. 
Biologically based therapies, including nutraceuticals, are commonly employed by 
parents of children with disabilities because CAM interventions do not have the same 
adverse side effects as pharmaceutical interventions 68. Thus, nutrition interventions, 
more specifically antioxidant therapies, as used in this study, need to remain under 
investigation as a potential CAM for addressing and hopefully improving ASD 
behavioral symptoms. 
  
Conclusion 
To the authors’ knowledge, to date, this is the first pilot study associating 
consumption of a nutraceutical, high antioxidant cacao, to behavioral outcomes in the 
ASD population from a parent’s perspective. Results from this study add to the existing 
literature on the potential benefits of antioxidants on improving behavior in children with 
ASD. Further robust randomized controlled trials are needed to further validate these 
positive findings.  
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 Table 1. Participant characteristics (N=16). 
  n % 
Age (Mean ± SD) 11.1 ± 3.6  
 
Male 
 
12 
 
75.0 
 
Grade 
K 
1 
2 
4 
5 
6 
7 
9 
10 
12 
 
 
2 
1 
1 
1 
2 
3 
2 
1 
2 
1 
 
 
12.5 
  6.3 
  6.3 
  6.3 
12.5 
18.8 
12.5 
  6.3 
12.5 
  6.3 
 
Verbal ability 
Non-verbal 
Limited verbal 
Verbal 
 
 
3 
2 
11 
 
 
18.8 
12.5 
68.8 
 
Ethnicity 
White 
Hispanic or Latino 
Black or African American 
Asian 
Native Hawaiian 
Mixed ethnicity 
 
 
5 
4 
1 
1 
1 
4 
 
 
31.3 
25.0 
6.3 
6.3 
6.3 
25.0 
 
Diagnosed by 
Pediatrician 
Neurologist 
Inland Regional Center 
Psychologist 
 
 
4 
5 
5 
2 
 
 
25.0 
31.3 
31.3 
12.5 
 
Employment 
Full time 
Part time 
Out of work and looking 
Home maker 
Out of work not looking 
 
 
7 
3 
1 
4 
1 
 
 
43.8 
18.8 
6.3 
25.0 
6.3 
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Table 1. Continued 
 
Education 
Some HS 
Some college 
Associate’s degree 
Bachelor’s degree  
Master’s degree 
 
Income 
$20,000-$34,999 
$35,000-$49,999 
$50,000-$74,999 
$75,000-$149,999 
$100,000-$149,999 
$150,000 or more 
n 
 
1 
2 
3 
6 
4 
 
 
2 
2 
2 
4 
5 
1 
% 
 
6.3 
12.5 
18.8 
37.5 
25.0 
 
 
12.5 
12.5 
12.5 
25.0 
31.3 
6.3 
 
Marital status 
Single 
Married 
Divorced 
Separated 
 
 
1 
13 
1 
1 
 
 
6.3 
81.3 
6.3 
6.3 
 
Custodya 
Mother 
Shared 
 
 
 
2 
1 
 
 
 
12.5 
6.3 
 
Abbreviations: SDC, Special Day Class; IEP, Individualized Education Program; RSP, 
Resource Specialist Program  
           aPercentages do not add to 100% because parents are married 
 
 
 
  
n % 
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Table 2. Child’s medical history and type of therapy (N=16). 
 n (%) 
  
Headaches 2 (12.5) 
 
ADHD 
 
 
4 (25.0) 
Anxiety/Depression 
 
Sleeping Disorder 
3 (18.8) 
 
1   (6.3) 
 
Hours of sleep per night 
4-6 hours 
7-8 hours 
9 hours or more 
 
 
2 (12.5) 
9 (56.2) 
5 (31.3) 
 
Medications 
Attention 
Anxiety 
Mood Disorder 
Headache 
Behavior 
 
 
4 (25.0) 
3 (18.8) 
2 (12.5) 
1   (6.3) 
3 (18.8) 
 
Type of Therapy 
Individual psychotherapy 
 
 
1    (6.3) 
Group psychotherapy 2  (12.5) 
Family therapy 1    (6.3) 
Speech therapy 15 (93.7) 
Occupational therapy  14 (87.5) 
Applied Behavior Analysis 11 (68.8) 
Physical therapy 4   (25.0) 
Early intervention 11 (68.8) 
Abbreviations: ADHD, Attention Deficit Hyperactivity Disorder 
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Table 3. Median (min, max) Scores for ABC-2 and ASRS over time. 
Scale Subscale Baseline Week 2 Week 4 P value* (η2) 
ABC-2 Irritability 13.0 (0,35) 13.0 (0,31) 7.0 (0,34) p= .03, η2 = 0.25 
 Social Withdrawal 13.0 (1,34)  9.0 (0.37) 7.5 (0,34) p=.01, η2 = 0.29 
 Stereotypic Behavior   3.5 (0,15)  3.0 (1,14) 1.0 (0,16) p=.05, η2 = 0.13 
 Hyperactivity/Noncompliance 15.0(4,42) 12.0 (2,39) 9.5 (0,42) p=.04, η2 = 0.20 
 Inappropriate Speech   3.0 (0,9)   2.0 (0,9) 1.5 (0,10) p=.22, η2 = 0.16 
ASRS Social/Communication 70.0 (58,85) 65.5 (52,82) 68.0 (43,85) p=.04, η
2 = 0.25 
 Unusual Behaviors 69.0 (45,83) 66.0 (7,74) 61.0 (43,74) p=.003, η2 = 0.20 
 Self-Regulation 65.0 (48,76) 64.0 (47,75) 60.0 (38,77) p=.02, η2 = 0.32 
 Total of 3 Subscales T Score 72.0 (54,83) 68.5 (50,77) 62.0 (45,79) p<.001, η2 = 0.54 
Abbreviations: ABC-2, Aberrant Behavior Checklist 2nd Edition; ASRS, Autism Spectrum Rating Scale, η2 
= effect size 
*Friedman Test 
** d η2 = Treatment Sum of Squares 
                 Total Sum of Squares 
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CHAPTER 4 
DISCUSSION 
 
In this pilot study, we conducted a prospective experimental clinical trial to 
examine the effects of high antioxidant cacao consumption on behaviors in children with 
Autism Spectrum Disorder. Teacher perceptions were recorded as rated on the Aberrant 
Behavior Checklist-2 (ABC-2) and Autism Spectrum Rating Scale (ASRS) at the 
beginning and end of the four-week study. The cacao intervention was well tolerated and 
no side effects were reported by any of the participants’ parents over the course of the 
intervention. The results of this study indicated that teachers perceived a significant 
improvement in their ASD student’s behavior in the ASRS scales of: 1) 
social/communication, 2) unusual behaviors, and 3) self-regulation. No significant 
changes were noted on any of the subscales on the ABC-2. The results of this study 
indicated that parents perceived a significant improvement in their ASD child’s behavior 
in the ASRS scales of: 1) Social/Communication, 2) Unusual Behaviors, and 3) Self-
Regulation. Significant improvements were also noted on the ABC-2 subscales of 1) 
Irritability, 2) Social Withdrawal, 3) Stereotypic Behavior, and 4) 
Hyperactivity/Noncompliance. Overall, median scores decreased, indicating that 
participants were less irritable, socially withdrawn, and reduced stereotypic behaviors. In 
addition, participants improved in their social/communication skills and self-regulation, 
and had less unusual behaviors. The results of this study are consistent with the findings 
from the N-Acetylcysteine (NAC) and ASD studies that found improvements in 
hyperactivity and irritability ABC-2 subscales 35,55,56. Based on these studies, there is 
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promising benefit of antioxidant-based therapies in targeting common behavioral 
symptoms in ASD 35,55,56.  
Overall, participant characteristics revealed that parents were well educated, of an 
above average socioeconomic status, and children came from a stable home as most 
parents were married. A previous study indicated that parents of children with ASD, who 
are more educated and affluent, tend to try alternative therapies and enroll their children 
in clinical trials more than others 70. 
Although there is limited research on antioxidants, specifically cacao, and the 
autistic population, previous literature on adults suggests the neuroprotective benefits of 
cacao. In recent reviews, the benefits of the cocoa bean and its derivatives were 
associated with improved cerebrovascular function, permeation of the blood brain barrier 
via flavanols (epicatechin and catechin), working memory, attention, processing speed, 
and learning 50,67. Furthermore, ingestion of cocoa flavanols in adults significantly 
improved cognitive scores, visual information processing, visual contrast sensitivity, and 
spatial memory 34,42,43. The above studies acknowledge that the underlying mechanisms 
of cocoa on brain health are still under investigation, however, observed benefits may be 
related to effects on endothelial function and blood flow which promote oxygen and 
nutrient delivery systemically. Although the research available on cocoa’s physiological 
and neurological benefit for adults is useful, there is still a gap in the literature on how 
cocoa can be used in the pediatric population, specifically those with neurocognitive 
disorders.  
Our study had some limitations. First, a lack of control group limits the 
generalizability of these results. Second, our assessments, although validated and reliable, 
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were self-report measures which may include biases. However, previous research 
suggests the impact that ASD behaviors have on the parent and so their observations of 
behavior change may be most accurate as they understand the intricacies of their child’s 
maladaptive behaviors 13. Behaviors associated with ASD not only affect the parent child 
dynamic but also dually stress both the parent and child individually 13. Additionally, 
parents may be accurate raters because their stress has been correlated with the severity 
of their child’s behaviors so if behaviors are more or less severe they would be directly 
impacted and thus able to report changes 71. Thirdly, nutritional intake was not monitored 
over the course of the study which means dietary confounders could have impacted 
results. In an attempt to control for dietary effects, we avoided enrolling participants near 
major holiday breaks, such as Christmas and Thanksgiving, where diet may change more 
drastically. Fourth, the study length may not have been enough to show more significant 
behavior change in the participants. Previous antioxidant studies used different study 
lengths ranging from eight weeks, 10 weeks, 12 weeks, and up to 30 weeks compared to 
four weeks in the present study 35,54-56. Furthermore, the results of this study 
demonstrated an overall improvement in four of five ABC-2 subscales and all three 
ASRS scales with the most significant changes being after two weeks of intervention. 
Without a control group, it is difficult to rule out the potential for a placebo effect. 
However, some of the non-significant findings between baseline and week two 
strengthens the interpretation of results by suggesting that the significant effects observed 
after two weeks may not simply be driven by parents’ belief but an actual intervention 
effect on behavior. 
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A major strength of the present study was the low attrition rate since only one 
participant withdrew from the study. Previous antioxidant and ASD studies did not 
mention total antioxidant activity of interventions used nor was amount of NAC based on 
anthropometric assessments of individual participants35,54-56. Thus, another strength of the 
present investigation is the analysis and report of total antioxidant activity of the cacao 
validating its use as an antioxidant intervention. It should be noted that because this was a 
pilot feasibility study, it seemed premature to include different intake concentrations of 
cacao for participants as previous literature on adults was inconsistent and limited. 
However, future studies need to consider offering different antioxidant concentrations 
based on body weight as nutritional needs differ across the lifespan. All participants were 
receiving one or more traditional therapies targeting core symptoms, however, it would 
be unethical and unrealistic to include ASD children who were not receiving any type of 
therapy.  
Future studies are recommended to run the intervention for longer time periods 
and measure changes throughout the study to determine when the effect occurs. Analysis 
of biomarkers including urine or serum blood samples will be imperative to determine 
any physiological changes in oxidative stress status. Comparing groups using different 
concentrations of cacao based on anthropometric assessments, such as weight, through 
randomized controlled trials will further validate if observed changes are in fact due to 
the antioxidant intervention.  
Complementary and alternative medicine (CAM) need to be researched to 
determine efficacious approaches in the ASD population with consideration of the child’s 
medical history and diet history before recommendations can be made61. Biologically 
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based therapies, including nutraceuticals, are commonly employed by parents of children 
with disabilities because CAM interventions do not have the same adverse side effects as 
pharmaceutical interventions68. Thus, nutrition interventions, more specifically 
antioxidant therapies, as used in this study, need to remain under investigation as a 
potential CAM for addressing and hopefully improving ASD behavioral symptoms. 
  
Conclusion 
To the authors’ knowledge, to date, this is the first pilot study associating 
consumption of a nutraceutical, high antioxidant cacao, to behavioral outcomes in the 
ASD population from both parent and teacher perspectives. Results from both studies add 
to the existing literature on the potential benefits of antioxidants on improving behavior 
in children with ASD. Further robust randomized controlled trials are needed to further 
validate these findings.  
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APPENDIX A 
PARENT INFORMED CONSENT FORM 
 
 
 
 
 
 
 
 
 
 
 
 
INFORMED CONSENT (Parent) 
 
 
TITLE: THE EFFECT OF HIGH ANTIOXIDANT CACAO 
ON BEHAVIORS IN CHILDREN WITH AUTISM 
SPECTRUM DISORDER  
 
SPONSOR:   School of Allied Health Professions, Loma Linda  
    University 
 
 
PRINCIPAL   Lee Berk, DrPH, Associate Dean for Research Affairs 
INVESTIGATOR   
 
CO-INVESTIGATOR Amy Sadek, Rehabilitation Science PhD Candidate 
     
 
WHY IS THIS STUDY BEING DONE? 
 
This study is to see if eating cacao changes Autistic behaviors in children.  
 
Your child can be in this study if you understand and read English and you are 18 years 
of age or older, and your child has autism and is between 5-12 years old. Your child must 
like 70% cacao and not be allergic. 
 
Children with food allergies, caffeine hypersensitivity, theobromine hypersensitivity, a 
history of seizures or epilepsy, a developmental age less than 24 months, or diabetics 
cannot be in this study. 
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Approximately 35 subjects will participate in this study. 
 
This study may last up to 4 weeks with 5 visits at your child’s school for approximately 
30 minutes per visit. The first visit will take up to an hour for all paperwork and initial 
questionnaires. 
 
HOW WILL I BE INVOLVED? 
 
This study involves the following: 
 When you come for the study, we will obtain informed consent for you and your 
child to be in the study.  
 You will explain to your child their level of involvement in a manner they can 
understand to the best of their ability. 
 Your child will also be offered a taste testing sample of the chocolate bar to be 
used in the study to see if they like it as that is a requirement to be included in the 
study. 
 On day one, you will fill out a Food Frequency Questionnaire based on your 
child’s typical dietary habits, an Autism Spectrum Rating Scale, an Aberrant 
Behavior Checklist, and the Parental Stress Index Questionnaire. 
 The Food Frequency Questionnaire asks how often your child consumes foods 
like bread, meat, sweets, vegetables, and fruit. The Autism Spectrum Rating Scale 
asks questions about play skills, social interaction skills, communication skills, 
rigid behaviors, and understanding of humor. The Aberrant Behavior Checklist 
asks questions about your child’s irritability, agitation, crying, social behavior, 
repetitive behaviors, speech, and hyperactivity. The Parental Stress Index asks 
questions about how you’re feeling as a parent, your child’s behavior, and your 
interaction with them.  
 Your child will consume 3 squares of the 70% dark chocolate every four hours 
daily for four weeks during waking hours between 8:00 a.m. and 8:00 p.m. 
 You will fill out the Autism Spectrum Rating Scale and the Aberrant Behavior 
Checklist at the end of week two and at the end of week four.  
 You will fill out the Parental Stress Index Questionnaire at the end of week four.  
 Your child’s special education teacher will also fill out the Autism Spectrum 
Rating Scale and the Aberrant Behavior Checklist at the beginning of week 1, end 
of week 2, and end of week 4. They will also give any doses of the cacao that are 
during school hours. 
 
WHAT ARE THE REASONABLY FORESEEABLE RISKS OR DISCOMFORTS 
I MIGHT HAVE? 
 
This study poses no greater risk to you than what you routinely encounter in day-to-day 
life.   Participating in this study will involve the following risks: possible breach of 
confidentiality and feeling uncomfortable answering questions about parental stress.  
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All records and research materials that identify you and your child will be held confidential. 
Any published document resulting from this study will not disclose your identity without 
your permission. Information identifying you will only be available to the study personnel.  
 
All data will be secured in a locked cabinet in a locked office.  
 
The use of your Protected Health Information is explained in the separate authorization 
form. 
 
WILL THERE BE ANY BENEFIT TO ME OR OTHERS?  
 
Although you may not personally benefit from this study, your participation may help 
clinicians and teachers when working with autistic children.  
 
WHAT ARE MY RIGHTS AS A SUBJECT? 
 
Your participation in this study is entirely voluntary.  You may refuse to participate or 
withdraw once the study has started.  Your decision whether or not to participate or 
terminate at any time will not affect your future standing with the researchers, the schools, 
or the Inland Empire Autism Assessment Center of Excellence.  You do not give up any 
legal rights by participating in this study. 
 
If, at any time, you feel uncomfortable with the questions on the surveys, you may refuse 
to answer questions.   
 
WHAT COSTS ARE INVOLVED? 
 
There is no cost to you for participating in this study. 
 
WILL I BE PAID TO PARTICIPATE IN THIS STUDY? 
 
 You will be paid a $50 gift card for completing this study in full. 
 
WHO DO I CALL IF I HAVE QUESTIONS?  
 
You may call 909-558-4647 or e-mail patientrelations@llu.edu for information and 
assistance with complaints or concerns about your rights in this study. 
 
 SUBJECT’S STATEMENT OF CONSENT  
 
 I have read the contents of the consent form and have listened to the verbal 
explanation given  
 by the investigator. 
 My questions concerning this study have been answered to my satisfaction.  
 This study has been explained to my child at a level she/he can comprehend and I 
give  
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      permission for my child to participate in the study. 
 Signing this consent document does not waive my rights nor does it release the 
investigators,  
 institution or sponsors from their responsibilities. 
 I may call Dr. Lee Berk during routine office hours at (909) 651-5828 (ext: 15828) if 
I have  
 additional questions. 
 I hereby give voluntary consent to participate in this study. 
 
I understand I will be given a copy of this consent form after signing it.  
 
 
 
 
Signature of Parent/Guardian  Printed Name of Parent/Guardian 
 
 
 
 
 
Date  Name of Child 
 
Authority to act for subject:____________________________________________ 
 
INVESTIGATOR’S STATEMENT  
I have reviewed the contents of this consent form with the person signing above. I have 
explained potential risks and benefits of the study. 
 
 
Signature of Investigator  Printed Name of Investigator 
 
 
 
 
Date   
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APPENDIX B 
SPECIAL EDUCATION TEACHER INFORMED CONSENT 
 
 
 
 
 
INFORMED CONSENT (Special Education Teacher) 
 
TITLE: THE EFFECT OF HIGH ANTIOXIDANT CACAO ON 
BEHAVIORS IN CHILDREN WITH AUTISM 
SPECTRUM DISORDER  
SPONSOR:   School of Allied Health Professions 
PRINCIPAL 
INVESTIGATOR: Lee Berk, DrPH, Associate Dean for Research Affairs  
CO-INVESTIGATOR: Amy Sadek, Rehabilitation Science PhD Candidate  
  
WHY IS THIS STUDY BEING DONE? 
 
The purpose of the study is to determine if consuming high antioxidant cacao changes the 
severity of Autistic behaviors.  
 
You are invited to be in this study because you are an English-literate special education 
teacher, 18 years of age or older. We enrolled a child you are teaching in our study and 
need your feedback. 
 
Approximately 35 subjects will participate in this study. 
 
This study may last up to 4 weeks with 5 visits at your school site for approximately 30 
minutes per visit.  
 
HOW WILL I BE INVOLVED? 
 
Participation in this study involves the following: 
 Following your school districts’ agreement to participate, we will obtain informed 
consent from you.  
 On day one, you will fill out an Autism Spectrum Rating Scale and an Aberrant 
Behavior Checklist for the child. 
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 Your student who is autistic will consume 3 squares of the 70% dark chocolate 
every four hours daily for four weeks during waking hours between 8:00 a.m. and 
8:00 p.m. 
 You will provide the doses that occur during school hours such as 8:00 a.m. and 
12:00 p.m. 
 You will fill out the Autism Spectrum Rating Scale and the Aberrant Behavior 
Checklist at the end of week two and at the end of week four.  
 
WHAT ARE THE REASONABLY FORESEEABLE RISKS OR DISCOMFORTS 
I MIGHT HAVE? 
 
This study poses no greater risk to you than what you routinely encounter in day-to-day 
life.   Participating in this study will involve the following risks: possible breach of 
confidentiality and feeling uncomfortable answering questions.  
 
All records and research materials that identify you and the child will be held confidential. 
Any published document resulting from this study will not disclose your identity without 
your permission. Information identifying you will only be available to the study personnel.  
 
All data will be secured in a locked cabinet in a locked office.  
 
WILL THERE BE ANY BENEFIT TO ME OR OTHERS?  
 
Although you may not personally benefit from this study, your participation may help 
clinicians and teachers when working with children with a diagnosis of Autism Spectrum 
Disorder. Results of the study can provide insights to practitioners and teachers while 
working with children with Autism Spectrum Disorder. 
 
WHAT ARE MY RIGHTS AS A SUBJECT? 
 
Your participation in this study is entirely voluntary.  You may refuse to participate or 
withdraw once the study has started.  Your decision whether or not to participate or 
terminate at any time will not affect your future standing with the researchers, the schools, 
or the Inland Empire Autism Assessment Center of Excellence.  You do not give up any 
legal rights by participating in this study. 
 
If, at any time, you feel uncomfortable with the questions on the surveys, you may refuse 
to answer questions.   
 
WHAT COSTS ARE INVOLVED? 
 
There is no cost to you for participating in this study. 
 
WILL I BE PAID TO PARTICIPATE IN THIS STUDY? 
 
No. 
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WHO DO I CALL IF I HAVE QUESTIONS?  
 
You may call 909-558-4647 or e-mail patientrelations@llu.edu for information and 
assistance with complaints or concerns about your rights in this study. 
 
 SUBJECT’S STATEMENT OF CONSENT  
 
 I have read the contents of the consent form and have listened to the verbal 
explanation given by the investigator. 
 My questions concerning this study have been answered to my satisfaction.  
 Signing this consent document does not waive my rights nor does it release the 
investigators, institution or sponsors from their responsibilities. 
 I may call Dr. Lee Berk during routine office hours at (909) 651-5828 (ext: 15828) if 
I have additional questions. 
 I hereby give voluntary consent to participate in this study. 
 
I understand I will be given a copy of this consent form after signing it.  
 
 
 
Signature of Subject  Printed Name of Subject 
 
 
 
 
Date   
 
 
 
INVESTIGATOR’S STATEMENT  
I have reviewed the contents of this consent form with the person signing above. I have 
explained potential risks and benefits of the study. 
 
 
Signature of Investigator  Printed Name of Investigator 
 
 
 
 
Date   
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APPENDIX C 
 
AUTHORIZATION FOR USE OF PROTECTED HEALTH INFORMATION 
 
 
 
INSTITUTIONAL REVIEW BOARD 
Authorization for Use of  
Protected Health Information (PHI) 
Per 45 CFR §164.508(b) 
RESEARCH PROTECTION PROGRAMS 
LOMA LINDA UNIVERSITY | Office of the Vice President of Research Affairs 
24887 Taylor Street, Suite 202 Loma Linda, CA 92350 
(909) 558-4531 (voice) / (909) 558-0131 (fax)/e-mail: irb@llu.edu 
 
 
 
TITLE OF STUDY: The Effect of High Antioxidant Cacao on Behaviors in Children 
with Autism Spectrum Disorder 
PRINCIPAL INVESTIGATOR: Lee Berk, DrPH 
Others who will use, collect, or 
share PHI: 
All Authorized Personnel 
 
Use of the terms “I,” “you” and “your” addresses, where appropriate, the 
study patient, the parent or legal representative if the study patient is a 
minor, any unborn fetus(es) and child(ren) once born.  The study named 
above may be performed only by using personal information relating to your 
health.  National and international data protection regulations give you the 
right to control the use of your medical information.  Therefore, by signing 
this form, you specifically authorize your medical information to be used or 
shared as described below. 
 
The following personal information, considered “Protected Health 
Information” (PHI) is needed to conduct this study and may include, but is 
not limited to: name, address, telephone number, date of birth, medical 
records and charts, height, weight, school of attendance, current therapy 
services the child receives such as but not limited to occupational therapy, 
physical therapy, and speech therapy. Medical history of food allergies, 
caffeine hypersensitivity, theobromine hypersensitivity, seizures or epilepsy, 
developmental age < 24 months, and diabetes will also be obtained. 
 
The individual(s) listed above will use or share this PHI in the course of this 
study with the Institutional Review Board (IRB) of Loma Linda University, 
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the sponsor of the study School of Allied Health Professions and its 
affiliates, government agencies such as the Food and Drug Administration 
(FDA), other research sites involved in this study, health care providers who 
provide services to you in connection with this study, central labs, central 
review centers and central reviewers. 
 
The main reason for sharing this information is to be able to conduct the 
study as described earlier in the consent form.  In addition, it is shared to 
ensure that the study meets legal, institutional, and accreditation standards.  
Information may also be shared to report adverse events or situations that 
may help prevent placing other individuals at risk.  
 
All reasonable efforts will be used to protect the confidentiality of your PHI, 
which may be shared with others to support this study, to carry out their 
responsibilities, to conduct public health reporting and to comply with the 
law as applicable.  Those who receive the PHI may share with others if they 
are required by law, and they may share it with others who may not be 
required to follow national and international “protected health information” 
(PHI) regulations such as the federal privacy rule. 
 
Subject to any legal limitations, you have the right to access any protected 
health information created during this study. You may request this 
information from the Principal Investigator named above but it will only 
become available after the study analyses are complete.   
 
 The authorization expires upon the conclusion of this research study. 
 
You may change your mind about this authorization at any time.  If this 
happens, you must withdraw your permission in writing. Beginning on the 
date you withdraw your permission, no new personal health information will 
be used for this study. However, study personnel may continue to use the 
health information that was provided before you withdrew your permission.  
If you sign this form and enter the study, but later change your mind and 
withdraw your permission, you will be removed from the study at that time.  
To withdraw your permission, please contact the Principal Investigator, Dr. 
Lee Berk, or study personnel at 909-651-5828 (ext 15828). 
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You may refuse to sign this authorization. Refusing to sign will not affect the 
present or future care you receive at this institution and will not cause any 
penalty or loss of benefits to which you are entitled.  However, if you do not 
sign this authorization form, you will not be able to take part in the study for 
which you are being considered.  You will receive a copy of this signed and 
dated authorization prior to your participation in this study. 
 
I agree that my personal health information may be used for the study 
purposes described in this form. 
 
 
Signature of Patient or Patient’s Legal 
Representative 
 
 
 Date  
Printed Name of Legal Representative (if any) 
 
 
 Representative’s Authority to Act for 
Patient 
Signature of Investigator Obtaining 
Authorization 
 Date  
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APPENDIX D 
 
CALIFORNIA EXPERIMENTAL SUBJECT’S BILL OF RIGHTS 
 
 
You have been asked to participate as a subject in an experimental clinical procedure. 
Before you decide whether you want to participate in the experimental procedure, you have 
a right to: 
  
1.   Be informed of the nature and purpose of the experiment. 
 
2. Be given an explanation of the procedures to be followed in the medical experiment, 
and any drug or device to be utilized. 
 
3. Be given a description of any attendant discomforts and risks reasonably to be expected 
from the experiment. 
 
4. Be given an explanation of any benefits to the subject reasonably to be expected from 
the experiment, if applicable. 
 
5. Be given a disclosure of any appropriate alternative procedures, drugs or devices that 
might be advantageous to the subject, and their relative risks and benefits. 
 
6. Be informed of the avenues of medical treatment, if any available to the subject after 
the experiment if complications should arise. 
 
7. Be given an opportunity to ask any questions concerning the experiment or the 
procedure involved. 
 
8. Be instructed that consent to participate in the medical experiment may be withdrawn 
at any time and the subject may discontinue participation in the medical experiment 
without prejudice. 
 
9. Be given a copy of any signed and dated written consent form used in relation to the 
experiment. 
 
10. Be given the opportunity to decide to consent or not to consent to a medical experiment 
without the intervention of any element of force, fraud, deceit, duress, coercion or 
undue influence on the subject's decision. 
 
I have carefully read the information contained above in the “California Experimental 
Subject’s Bill of Rights” and I understand fully my rights as a potential subject in a medical 
experiment involving people as subjects. 
       
           ________________________                _________________________________ 
                  Date                                                           Patient  
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APPENDIX E 
 
PARTICIPANT’S DEMOGRAPHIC FORM  
1. Name of Child _____________________________ 
 
2. Name of Parent (Informant) ___________________ 
 
3. Date of Birth _______________________________ 
 
4. Current Grade ______________________________ 
 
5. Gender:  
 Male 
 Female 
 
6. How was your child diagnosed with Autism Spectrum Disorder?  
 Pediatrician 
 Neurologist 
 School Psychologist 
 Inland Empire Autism Assessment Center of Excellence 
 Other (please specify):___________________________ 
 
7. Ethnicity: (Please check only one answer) 
 White 
 Hispanic or Latino 
 Black or African American 
 Native American or American Indian 
 Asian  
 Native Hawaiian or Other Pacific Islander 
 Other (please specify): _____________________________ 
 
8. Current Employment: (Please check only one answer) 
 Full-time 
 Part-time 
 Self-employed 
 Out of work and looking for work 
 Out of work but not currently looking for work (unemployed) 
 Homemaker 
 Military 
 Retired 
 Unable to work 
 Other (please specify): ______________________________ 
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9. Highest Level of Education: (Please check only one answer) 
 No schooling completed 
 Primary school to 8th grade 
 Some high school, no diploma 
 High school graduate, diploma or the equivalent (GED) 
 Some college credit, no degree 
 Trade/technical/vocational training  
 Associate Degree 
 Bachelor’s Degree 
 Master’s Degree 
 Doctorate Degree 
 
10. What is your current marital status? (Please check only one answer) 
 Single 
 Married 
 Divorced 
 Separated 
 Widowed  
 
11. If divorced, who has custody of the child? 
 Mother 
 Father 
 Shared  
 Other (please specify): ___________________________ 
 
12. What is your annual household income? (Please check only one answer) 
 Less than $20,000 
 $20,000 - $34,999 
 $35,000 - $49,999 
 $50,000 - $74,999 
 $75,000 - $99,999 
 $100,000 - $149,999 
 $150,000 or more 
 
13. Have any of the following stress events occurred in your life? (Check all that 
apply) 
 Parents divorced or separated  
 Family illness 
 Death in the family 
 Parent changed job 
 Change schools 
 Family moved  
 Family financial problems  
 Other (please specify): _________________________ 
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14. Child’s Medical History: (Check all that apply) 
 Seizures or Epilepsy 
 Diabetes  
 Food allergies 
 Headaches  
 Migraine headaches 
 Attention Deficit Hyperactivity Disorder (ADHD)  
 Anxiety or Depression 
 Autism Spectrum Disorder 
 Eating Disorder 
 Sleeping Disorder 
 Other: (please specify): _________________________ 
 
15. Average hours per night your child sleeps on weekdays: (Please check only one 
answer) 
 0-3 hours 
 4-6 hours 
 7-8 hours 
 9 hours or more  
 
16. Average hours per night your child sleeps on weekends: (Please check only one 
answer) 
 0-3 hours 
 4-6 hours 
 7-8 hours 
 9 hours or more 
 
17. Has your child ever had any of the following forms of treatment? (Check all that 
apply) 
 Individual psychotherapy  
 If so, for how long: ___________________________ 
 Group psychotherapy  
 If so, for how long: ___________________________ 
 Family therapy with child 
 If so, for how long: ___________________________ 
 Speech therapy 
 If so, for how long: ___________________________ 
 Occupational therapy 
 If so, for how long: ___________________________ 
 Applied Behavioral Analysis (ABA) 
 If so, for how long: ___________________________ 
 Physical therapy 
 If so, for how long: ___________________________ 
 Early Intervention (Inland Regional Center, Early Head Start) 
 If so, for how long: ___________________________ 
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18. Does your child have an Individualized Education Program? 
 No  
 Yes  
 
 
19. What classroom setting is your child currently in? 
 Special education: SDC mild/moderate 
 Special education: SDC moderate/severe 
 Special education: SDC severe/profound 
 Mostly special education with some mainstreaming 
 General education with RSP support 
 General education (full inclusion) 
 Has a “one on one” aid in special education or general education 
 Other (please specify):_______________________ 
 
20. Where did you get a copy of the flyer to participate? (Check all that apply) 
 Inland Empire Autism Assessment Center of Excellence  
 WonderLAB 
 Loma Linda University Outpatient Pediatric Rehabilitation Center 
 Loma Linda University Interdisciplinary Outreach Clinic  
 Drayson Center (Loma Linda)  
 SenseAbilities  
 Precious Hearts Academy 
 High Desert Speech and Language Center Inc. 
 Inland Regional Center  
 Pediatric Therapy Associates (Chino) 
 Anaheim Hills Pediatric Therapy Inc. 
 Five Oaks Speech Clinic 
 Horizon Therapy Services 
 Nichols Speech Therapy  
 Up & Movin Pediatric Therapy 
 Redlands Community Hospital 
 Autism Society Inland Empire (Facebook or newsletter) 
 Clinical Trials Website 
 Facebook  
 Email  
 Other (please specify): _____________________________ 
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APPENDIX F 
ABERRANT BEHAVIOR CHECKLIST 2ND EDITION QUESTIONNAIRE 
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APPENDIX G 
AUTISM SPECTRUM RATING SCALE 
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APPENDIX H 
PARENTAL STRESS INDEX SHORT FORM 
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 104 
APPENDIX I 
YOUTH AND ADOLESCENT FOOD FREQUENCY QUESTIONNAIRE 
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APPENDIX J 
DATA COLLECTION FORM 
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APPENDIX K 
 
LETTER OF RECRUITMENT FOR FLYER DISTRIBUTION 
 
Date:  
 
Letter of Agreement to Conduct Research  
 
 
To Whom It May Concern,  
 
I, ______________________________________, ____________________________, of  
 (name)       (title) 
 
_____________________________________, agree to participate in a research study by  
 (organization/institution) 
 
allowing the research recruitment to take place at (Name of site) per research projects’ 
protocol. This doctoral graduate student who is a licensed Occupational Therapist is 
conducting a research study through Loma Linda University, School of Allied Health 
Professions. The study is entitled “The Effect of High Antioxidant Cacao on Behaviors in 
Children with Autism Spectrum Disorder.” 
 
 
 
____________________________________  ______________________ 
Signature       Date 
 
 
_____________________________________  
Institution 
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APPENDIX L 
 
ALLERGIC REACTION FACT SHEET 
 
 
Potential allergic reactions to eating chocolate*: 
 
“Chocolate may cause acne, allergic skin reactions, bloating, colic in infants, 
constipation, decreased bone density, dental caries, eczema, gas, headaches, improved 
insulin sensitivity, increased cholesterol levels, increased insulin levels, irregular heart 
rhythms, increased oxalate levels in urine, irritable bowel syndrome, irritability, 
jitteriness, kidney damage and disorders, migraines, nausea, neck pain, nervousness, 
shakiness, sleep disturbances, stomach rumbling, stomach upset, swelling under the skin, 
unpleasant taste, upset stomach, vomiting, weight gain.” 
 
In the event that your child/student experiences any of these side effects: 
 
1. Stop chocolate consumption immediately. 
2. Consult with the school nurse if allergic reaction happens at school. 
3. Consult your child’s health care provider immediately if they experience side 
effects at home. 
4. Call 911. 
5. Report incident to Dr. Lee Berk at (909) 651-5828 (ext: 15828) and Amy Sadek at 
951-212-2104. 
 
 
 
 
 
 
 
 
 
 
 
Reference 
 
*Mayo Clinic. (2013, November 1). Drug and Supplements: Chocolate. Retrieved from 
http://www.mayoclinic.org/drugs-supplements/chocolate/safety/hrb-20058898 
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APPENDIX M 
 
FLYER FOR RECRUITING PARTICIPANTS 
 
 
